Propanc Biopharma (PPCB) 10-Q 14 Feb 25 2025 Q2 Quarterly report Financial data

Cover

Cover - $ / shares	6 Months Ended
	Dec. 31, 2024	Feb. 12, 2025
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2024
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2025
Current Fiscal Year End Date	--06-30
Entity File Number	000-54878
Entity Registrant Name	PROPANC BIOPHARMA, INC.
Entity Central Index Key	0001517681
Entity Tax Identification Number	33-0662986
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	302
Entity Address, Address Line Two	6 Butler Street
Entity Address, City or Town	Camberwell
Entity Address, Country	AU
Entity Address, Postal Zip Code	3124
City Area Code	+61-03
Local Phone Number	9882-0780
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		15,372
Entity Listing, Par Value Per Share	$ 0.001

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets	Dec. 31, 2024 USD ($)	Jun. 30, 2024 USD ($)
CURRENT ASSETS:
Cash	$ 14,633	$ 21,085
GST tax receivable	1,973	2,950
Prepaid expenses and other current assets	1,378	1,406
TOTAL CURRENT ASSETS	17,984	25,441
Deferred offering costs	52,117	27,117
Security deposit - related party	1,855	2,008
TOTAL ASSETS	78,533	72,365
CURRENT LIABILITIES:
Accounts payable	1,223,254	1,213,335
Accrued expenses and other payables	899,262	792,190
Accrued interest	135,351	94,612
Notes payable, net of discount	168,217	204,694
Convertible notes, net of discounts and including put premiums	409,799	399,325
Embedded conversion option liabilities	131,585	133,886
Employee benefit liability	611,318	639,371
TOTAL CURRENT LIABILITIES	4,154,964	3,792,782
NON-CURRENT LIABILITIES:
TOTAL NON-CURRENT LIABILITIES	82,328	58,642
TOTAL LIABILITIES	4,237,292	3,851,424
Commitments and Contingencies (See Note 8)
STOCKHOLDERS’ DEFICIT:
Common stock, $0.001 par value; 10,000,000,000 shares authorized; 14,508 and 7,980 shares issued and outstanding as of December 31, 2024 and June 30, 2024, respectively	14	8
Additional paid-in capital	61,878,549	61,696,049
Accumulated other comprehensive income	1,491,868	1,269,581
Accumulated deficit	(67,482,713)	(66,698,220)
Treasury stock ($0.001 share)	(46,477)	(46,477)
TOTAL STOCKHOLDERS’ DEFICIT	(4,158,759)	(3,779,059)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	78,533	72,365
Series B Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT:
Preferred stock, value
Related Party [Member]
CURRENT ASSETS:
Operating lease right-of-use assets, net - related party	6,577	17,799
CURRENT LIABILITIES:
Loan payable	350,544	71,629
Operating lease liability - related party, current portion	7,298	19,362
NON-CURRENT LIABILITIES:
Loan payable - long-term - related party, net of discount	82,328	58,642
Nonrelated Party [Member]
CURRENT LIABILITIES:
Loan payable	145,091	145,091
Former Director [Member]
CURRENT LIABILITIES:
Loan payable	45,754	49,528
Due to former director - related party	$ 27,491	$ 29,759

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2024	Jun. 30, 2024
Preferred stock, shares authorized	1,500,005	1,500,005
Preferred stock, par value	$ 0.01	$ 0.01
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	10,000,000,000	10,000,000,000
Common stock, shares issued	14,508	7,980
Common stock, shares outstanding	14,508	7,980
Treasury stock price per share	$ 0.001	$ 0.001
Series B Preferred Stock [Member]
Preferred stock, shares authorized	5	5
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares issued	1	1
Preferred stock, shares outstanding	1	1

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
REVENUE
Revenue
OPERATING EXPENSES
Administration expenses	153,593	318,185	374,352	712,013
Occupancy expenses - related party	5,401	5,857	13,718	13,006
Research and development	54,388	114,022	116,102	130,264
TOTAL OPERATING EXPENSES	213,382	438,064	504,172	855,283
LOSS FROM OPERATIONS	(213,382)	(438,064)	(504,172)	(855,283)
OTHER INCOME (EXPENSE)
Interest expense	(118,943)	(264,462)	(205,173)	(442,696)
Interest income		16	1	33
Derivative expense	(8,559)	(45,658)	(35,741)	(123,379)
Change in fair value of derivative liabilities	13,581	(1,771)	66,368	302,158
Gain (loss) on extinguishment of debt, net	(18,759)	(211)	(30,078)	34,099
Foreign currency transaction gain (loss)	(84,121)	37,146	(75,698)	21,198
TOTAL OTHER INCOME (EXPENSE), NET	(216,801)	(274,940)	(280,321)	(208,587)
LOSS BEFORE TAXES	(430,183)	(713,004)	(784,493)	(1,063,870)
Tax benefit		128,620		128,620
NET LOSS	(430,183)	(584,384)	(784,493)	(935,250)
Deemed Dividend		(34,585)		(177,160)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS	$ (430,183)	$ (618,969)	$ (784,493)	$ (1,112,410)
BASIC NET LOSS PER SHARE AVAILABLE TO COMMON STOCKHOLDERS	$ (32.23)	$ (1,559.55)	$ (67.64)	$ (3,835.55)
DILUTED NET LOSS PER SHARE AVAILABLE TO COMMON STOCKHOLDERS	$ (32.23)	$ (1,559.55)	$ (67.64)	$ (3,835.55)
BASIC WEIGHTED AVERAGE SHARES OUTSTANDING	13,347	397	11,597	290
DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING	13,347	397	11,597	290
OTHER COMPREHENSIVE INCOME (LOSS)
Unrealized foreign currency translation gain (loss)	$ 321,230	$ (134,480)	$ 222,287	$ (60,806)
TOTAL OTHER COMPREHENSIVE INCOME (LOSS)	321,230	(134,480)	222,287	(60,806)
TOTAL COMPREHENSIVE LOSS	$ (108,953)	$ (753,449)	$ (562,206)	$ (1,173,216)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Common Stock Issuable [Member]	Additional Paid-in Capital [Member]	Subscription Receivable [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock, Common [Member]	Total
Balance at Jun. 30, 2023					$ 60,319,154		$ (64,684,732)	$ 1,294,876	$ (46,477)	$ (3,117,179)
Balance, shares at Jun. 30, 2023		1	101	27
Issuance of common stock for conversion of convertible debt, conversion fees and accrued interest					229,190					229,190
Issuance of common stock for conversion of convertible debt, conversion fees and accrued interest, shares			82	10
Issuance of common stock for alternate cashless exercise of warrants
Issuance of common stock for alternate cashless exercise of warrants, shares			38
Issuance of common stock for issuable shares
Issuance of common stock for issuable shares, shares			27	(27)
Reclassification of put premium upon debt conversion					34,838					34,838
Relative fair value of warrant granted in connection with a loan payable - related party					141,084					141,084
Foreign currency translation gain (loss)								73,674		73,674
Deemed dividend upon alternate cashless exercise of warrants					142,575		(142,575)
Net loss							(350,866)			(350,866)
Balance at Sep. 30, 2023					60,866,841		(65,178,173)	1,368,550	(46,477)	(2,989,259)
Balance, shares at Sep. 30, 2023		1	247	10
Balance at Jun. 30, 2023					60,319,154		(64,684,732)	1,294,876	(46,477)	(3,117,179)
Balance, shares at Jun. 30, 2023		1	101	27
Foreign currency translation gain (loss)										(60,806)
Net loss										(935,250)
Balance at Dec. 31, 2023					61,054,772	(8,822)	(65,797,142)	1,234,070	(46,477)	(3,563,599)
Balance, shares at Dec. 31, 2023		1	603	0
Balance at Sep. 30, 2023					60,866,841		(65,178,173)	1,368,550	(46,477)	(2,989,259)
Balance, shares at Sep. 30, 2023		1	247	10
Issuance of common stock for conversion of convertible debt, conversion fees and accrued interest					92,057					92,057
Issuance of common stock for conversion of convertible debt, conversion fees and accrued interest, shares			278
Issuance of common stock for alternate cashless exercise of warrants
Issuance of common stock for alternate cashless exercise of warrants, shares			44
Issuance of common stock for issuable shares
Issuance of common stock for issuable shares, shares			10	(10)
Reclassification of put premium upon debt conversion					52,467					52,467
Foreign currency translation gain (loss)								(134,480)		(134,480)
Deemed dividend upon alternate cashless exercise of warrants					34,585		(34,585)
Net loss							(584,384)			(584,384)
Issuance of common stock for cash					8,822	(8,822)
Issuance of common stock for cash, shares			23
Balance at Dec. 31, 2023					61,054,772	(8,822)	(65,797,142)	1,234,070	(46,477)	(3,563,599)
Balance, shares at Dec. 31, 2023		1	603	0
Balance at Jun. 30, 2024			$ 8		61,696,049		(66,698,220)	1,269,581	(46,477)	(3,779,059)
Balance, shares at Jun. 30, 2024		1	7,980
Issuance of common stock for conversion of convertible debt, conversion fees and accrued interest			$ 3		99,888					99,891
Issuance of common stock for conversion of convertible debt, conversion fees and accrued interest, shares			3,237
Reclassification of put premium upon debt conversion					9,336					9,336
Foreign currency translation gain (loss)								(98,943)		(98,943)
Net loss							(354,310)			(354,310)
Issuance of common stock for services					15,000					15,000
Issuance of common stock for services, shares			250
Balance at Sep. 30, 2024			$ 11		61,820,273		(67,052,530)	1,170,638	(46,477)	(4,108,085)
Balance, shares at Sep. 30, 2024		1	11,467
Balance at Jun. 30, 2024			$ 8		61,696,049		(66,698,220)	1,269,581	(46,477)	(3,779,059)
Balance, shares at Jun. 30, 2024		1	7,980
Foreign currency translation gain (loss)										222,287
Net loss										(784,493)
Balance at Dec. 31, 2024			$ 14		61,878,549		(67,482,713)	1,491,868	(46,477)	(4,158,759)
Balance, shares at Dec. 31, 2024		1	14,508
Balance at Sep. 30, 2024			$ 11		61,820,273		(67,052,530)	1,170,638	(46,477)	(4,108,085)
Balance, shares at Sep. 30, 2024		1	11,467
Issuance of common stock for conversion of convertible debt, conversion fees and accrued interest			$ 3		58,276					58,279
Issuance of common stock for conversion of convertible debt, conversion fees and accrued interest, shares			3,041
Foreign currency translation gain (loss)								321,230		321,230
Net loss							(430,183)			(430,183)
Balance at Dec. 31, 2024			$ 14		$ 61,878,549		$ (67,482,713)	$ 1,491,868	$ (46,477)	$ (4,158,759)
Balance, shares at Dec. 31, 2024		1	14,508

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				6 Months Ended		12 Months Ended
	Dec. 31, 2024	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2024	Dec. 31, 2023	Jun. 30, 2024
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (430,183)	$ (354,310)	$ (584,384)	$ (350,866)	$ (784,493)	$ (935,250)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Issuance of common stock for services					15,000
Foreign currency transaction loss (gain)					75,698	(21,198)
Depreciation expense						248
Amortization of debt discounts					133,644	164,904
Amortization of right-of-use assets					9,866	10,871
Change in fair value of derivative liabilities	(13,581)		1,771		(66,368)	(302,158)
Derivative expense	8,559		45,658		35,741	123,379
Loss (gain) on extinguishment of debt, net	18,759		211		30,078	(34,099)
Non-cash interest expense					4,582	1,597
Accretion of put premium						234,615
Changes in Assets and Liabilities:
GST receivable					752	(977)
Prepaid expenses and other assets					(80)	(5,877)
Refundable advance deposit						(123,127)
Deferred offering costs					(25,000)
Accounts payable					102,374	169,359
Employee benefit liability					20,666	23,897
Accrued expenses and other payables					166,993	96,924
Accrued interest					49,350	35,323
Operating lease liability					(10,589)	(10,773)
NET CASH USED IN OPERATING ACTIVITIES					(241,786)	(572,342)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from convertible promissory notes, net of original issue discounts and issue costs					80,000	477,500
Repayment of convertible note						(142,909)
Repayment of notes					(98,400)
Proceeds from note payable					35,000	120,000
Proceeds from loans payable - related parties					278,915	169,685
NET CASH PROVIDED BY FINANCING ACTIVITIES					295,515	624,276
Effect of exchange rate changes on cash					(60,181)	9,669
NET (DECREASE) INCREASE IN CASH					(6,452)	61,603
CASH AT BEGINNING OF PERIOD		$ 21,085		$ 10,047	21,085	10,047	$ 10,047
CASH AT END OF PERIOD	$ 14,633		$ 71,650		14,633	71,650	$ 21,085
Supplemental Disclosure of Cash Flow Information
Interest					17,599	6,189
Income Tax
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Subscription receivable						8,822
Reduction of put premium related to conversions of convertible notes					9,336	87,305
Conversion of convertible notes and accrued interest to common stock					71,836	203,365
Debt discounts related to derivative liability					80,000	125,000
Relative fair value of warrant granted in connection with a loan payable - related party						141,084
Deemed dividend upon alternate cashless exercise of warrants						$ 177,160

NATURE OF OPERATIONS AND SUMMAR

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES	6 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES	NOTE 1 – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES Nature of Operations Propanc Biopharma, Inc. (the “Company,” “we,” “us” or “our”) is based in Camberwell, Victoria Australia. Since its inception, substantially all of the operations of the Company have been focused on the development of new cancer treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to prevent the cancer from returning and spreading. The Company anticipates establishing global markets for its technologies. Our lead product candidate, which we refer to as PRP, is an enhanced pro-enzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. It is currently in the preclinical phase of development. The Company was originally formed in Melbourne, Victoria, Australia on October 15, 2007 as Propanc PTY LTD. On November 23, 2010, Propanc Health Group Corporation was incorporated in the State of Delaware, and in January 2011, to reorganize the Company, all of the outstanding shares of Propanc PTY LTD were acquired on a one-for-one basis by Propanc Health Group Corporation, with Propanc PTY LTD becoming a wholly-owned subsidiary of the Company. On July 22, 2016, the Company formed another wholly-owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose of submitting an orphan drug application to the European Medicines Agency as a small and medium-sized enterprise. As of December 31, 2024, there has been no activity within this entity. Effective April 20, 2017, the Company changed its name to “Propanc Biopharma, Inc.” to reflect the Company’s stage of operations and development better. In July 2020, a world-first patent was granted in Australia for the cancer treatment method patent family. Presently, there are 84 granted, allowed, or accepted patents and 6 patents filed, or under examination in key global jurisdictions relating to the use of proenzymes against solid tumors, covering the lead product candidate PRP. On August 7, 2024, the Company received written consent in lieu of a meeting by the holders of a majority of the voting power of the Company’s outstanding capital stock as of August 7, 2024 and the Company’s Board of Directors approving such actions as are necessary for the Company to proceed to, and the Company accordingly intends to, effectuate and execute a reverse stock split of the Company’s issued and outstanding shares of common stock at a ratio of one post-split share per sixty thousand pre-split shares (1:60,000) The Company hopes to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer by filing additional patent applications as it advances its lead product candidate, PRP, through various stages of development. Basis of Presentation The Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q (this “Quarterly Report”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly our consolidated results of operations for the six months ended December 31, 2024 and 2023 and cash flows for the six months ended December 31, 2024 and 2023 and our consolidated financial position at December 31, 2024 have been made. The Company’s results of operations for the six months ended December 31, 2024 are not necessarily indicative of the operating results to be expected for the full fiscal year ending June 30, 2025. Certain information and disclosures normally included in the notes to the Company’s annual audited consolidated financial statements have been condensed or omitted from the Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report. Accordingly, these interim unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2024. The June 30, 2024 balance sheet is derived from those statements. Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of Propanc Biopharma, Inc., the parent entity, and its wholly-owned subsidiary, Propanc PTY LTD. All inter-company balances and transactions have been eliminated in consolidation. Propanc (UK) Limited was an inactive wholly-owned subsidiary through December 31, 2024 and still remains inactive. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 (Unaudited) Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives of long-lived assets, valuation of the collectability of a refundable advance deposit, present value of the operating lease liability and related right-of-use asset, valuation of derivatives, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates. Foreign Currency Translation and Other Comprehensive Income (Loss) The Company’s wholly-owned subsidiary’s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into the Company’s reporting currency, which is the United States dollar ($) and/or (USD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “Accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency translations are included in the statements of operations and comprehensive income (loss) as a component of other comprehensive income (loss). There have been no significant fluctuations in the exchange rate for the conversion of Australian dollars to USD after the balance sheet date. Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the consolidated balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency included in the consolidated results of operations as incurred. Effective fiscal year 2021, the parent company determined that the intercompany loans will not be repaid in the foreseeable future and thus, per Accounting Standards Codification (“ASC”) 830-20-35-3, gains and losses from measuring the intercompany balances are recorded within cumulative translation adjustment, a component of accumulated other comprehensive income (loss). As of December 31, 2024 and 2023, the Company recognized a cumulative exchange gain (loss) of approximately ($ 1,573,000 408,000 As of December 31, 2024 and June 30, 2024, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: SCHEDULE OF TRANSACTION EXCHANGE RATES December 31, 2024 June 30, 2024 Exchange rate on balance sheet dates USD : AUD exchange rate 0.6183 0.6693 Average exchange rate for the period USD : AUD exchange rate 0.6594 0.6557 The change in Accumulated Other Comprehensive Income by component during the six months ended December 31, 2024 was as follows: SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME Foreign Balance, June 30, 2024 $ 1,269,581 Unrealized foreign currency translation gain 222,287 Ending balance, December 31, 2024 $ 1,491,868 Fair Value of Financial Instruments and Fair Value Measurements The Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and cash equivalents, receivables, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current interest rates available for debt with similar terms and maturities are substantially the same. The Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Also see Note 11 - Derivative Financial Instruments and Fair Value Measurements. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 (Unaudited) Cash and Cash Equivalents Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the balance sheets. There were no Refundable Advance Deposit In August 2023, the Company paid a refundable advance deposit of $ 120,958 120,958 Deferred Offering Costs The Company complies with the requirements of ASC 340, Other Assets and Deferred Costs, with regards to offering costs. Prior to the completion of an offering, offering costs are capitalized and consist principally of professional, underwriting and other expenses incurred through the balance sheet date that are directly related to the Company’s proposed public offering. The deferred offering costs are charged to additional paid-in capital or as a discount to debt, as applicable, upon the completion of an offering or to expense if the offering is not completed. As of December 31, 2024 and June 30, 2024, the Company had recorded $ 52,117 27,117 Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method. The depreciable amount is the cost less its residual value. The estimated useful lives are as follows: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES Machinery and equipment - 5 Furniture - 7 Patents Patents are stated at cost and amortized on a straight-line basis over the estimated future periods if and once the patent has been granted by a regulatory agency. However, the Company will expense any patent costs as long as we are in the startup stage. Accordingly, as the Company’s products are not currently approved for market, all patent costs incurred from 2013 through December 31, 2024 were expensed immediately. This practice of expensing patent costs immediately ends when a product receives market authorization from a government regulatory agency. Impairment of Long-Lived Assets In accordance with ASC 360-10, “Long-lived assets,” which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. Employee Benefit/Liability Liabilities arising in respect of wages and salaries, accumulated annual leave, accumulated long service leave and any other employee benefits expected to be settled within twelve months of the reporting date are measured based on the employee’s remuneration rates applicable at the reporting date. All other employee benefit liabilities are measured at the present value of the estimated future cash outflow to be made in respect of services provided by employees up to the reporting date. All employee liabilities are owed within the next twelve months. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 (Unaudited) Australian Goods and Services Tax (“GST”) Revenues, expenses and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office. Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows. As of December 31, 2024 and June 30, 2024, the Company was owed $ 1,973 2,950 Derivative Instruments ASC Topic 815, Derivatives and Hedging Convertible Notes With Variable Conversion Options The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into shares of the Company’s common stock, par value $ 0.001 Distinguishing Liabilities from Equity Income Taxes The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. The Company follows ASC 740 “ Accounting for Income Taxes The Company follows ASC 740, Sections 25 through 60, “ Accounting for Uncertainty in Income Taxes Research and Development Costs and Tax Credits In accordance with ASC 730-10, “Research and Development-Overall,” 116,102 130,264 The Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income, then the Company can receive the credit which reduces its income tax liability. If the Company has net losses, then the Company may still receive a cash payment for the credit, however, the Company’s net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as a tax benefit, in operations, upon receipt. Stock Based Compensation The Company records stock-based compensation in accordance with ASC 718, “ Stock Compensation The Company adopted ASU 2018-07 and accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period. The Company used the modified prospective method of adoption. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 (Unaudited) Revenue Recognition The Company applies ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures. Subject to these criteria, the Company intends to recognize revenue relating to royalties on product sales in the period in which the sale occurs and the royalty term has begun. Legal Expenses All legal costs for litigation are charged to expense as incurred. Leases The Company follows ASC Topic 842, Leases (Topic 842) and applies the package of practical expedients, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 months or less. Operating lease right of use assets (“ROU”) represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses. Basic and Diluted Net Loss Per Common Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. Each holder of the convertible notes has agreed to a 4.99 SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS December 31, 2024 December 31, 2023 (Unaudited) (Unaudited) Stock Options - - Stock Warrants with no designations 250 250 Series A Warrants as if converted at alternate cashless exercise price 33,173 33,195 Series B Warrants - - Series C Warrants as if converted at alternate cashless exercise price * 152,933 152,933 Unvested restricted stock - - Convertible Debt 44,971 893 Total 231,327 187,271 * Only convertible ratably upon exercise of Series B Warrants Recent Accounting Pronouncements We have reviewed the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. We have carefully considered the new pronouncements that alter previous generally accepted accounting principles and do not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management. In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic 815-40), which eliminates the beneficial conversion and cash conversion accounting models for convertible instruments, amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions, and modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS calculation. The standard is effective for annual periods beginning after December 15, 2023 for smaller reporting companies, and interim periods within those reporting periods. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those reporting periods. The adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements or disclosures. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 (Unaudited)

GOING CONCERN

GOING CONCERN	6 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 2 – GOING CONCERN The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with US GAAP, which contemplate continuation of the Company as a going concern. For the six months ended December 31, 2024, the Company had no revenues, had a net loss of $ 784,493 241,786 4,136,980 4,158,759 67,482,713 The unaudited condensed consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty. Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to fulfill its development activities, acceptance of the Company’s patent applications, obtaining additional sources of suitable and adequate financing and ultimately achieving a level of sales adequate to support the Company’s cost structure and business plan. The Company’s ability to continue as a going concern is also dependent on its ability to further develop and execute on its business plan. However, there can be no assurances that any or all of these endeavors will be successful.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	6 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 3 – PROPERTY AND EQUIPMENT Property and equipment consist of the following As of December 31, 2024 and June 30, 2024. SCHEDULE OF PROPERTY PLANT AND EQUIPMENT December 31, 2024 June 30, 2024 (Unaudited) Office equipment at cost $ 23,597 $ 25,543 Less: Accumulated depreciation (23,597 ) (25,543 ) Total property, plant, and equipment $ - $ - Depreciation expense for the six months ended December 31, 2024 and 2023 were $ 0 248

DUE TO FORMER DIRECTOR - RELATE

DUE TO FORMER DIRECTOR - RELATED PARTY	6 Months Ended
	Dec. 31, 2024
Due To Former Director - Related Party
DUE TO FORMER DIRECTOR - RELATED PARTY	NOTE 4 – DUE TO FORMER DIRECTOR - RELATED PARTY Due to former director – related party represents unsecured advances made primarily by a former director for operating expenses on behalf of the Company, such as intellectual property and formation expenses. The expenses were paid for on behalf of the Company and are due upon demand. The Company is currently not being charged interest under these advances. The total amount owed the former director at December 31, 2024 and June 30, 2024 were $ 27,491 29,759

LOANS

LOANS	6 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
LOANS	NOTE 5 – LOANS Loan from Former Director - Related Party Loan from the Company’s former director at December 31, 2024 and June 30, 2024 were $ 45,754 49,528 Loans payable - Related Parties Between November 2023 and May 2024, an institutional investor affiliated with one of our directors, Josef Zelinger, loaned the Company an aggregate of $ 71,629 85,000 57,639 Effective August 1, 2024, the Company entered into and closed a loan agreement with an institutional investor affiliated with one of our directors, Josef Zelinger, pursuant to which the investor loaned the Company an aggregate principal amount of $ 150,000 98,060 November 1, 2024 12 18 35 Between November 2024 and December 2024, an institutional investor affiliated with one of our directors, Josef Zelinger, loaned the Company an aggregate of $ 15,000 9,731 Effective December 3, 2024, the Company entered into and closed a loan agreement with an institutional investor affiliated with one of our directors, Josef Zelinger, pursuant to which the investor loaned the Company an aggregate principal amount of $ 175,000 113,485 70,000 105,000 12 18 The loans payable – related parties amounted to $ 350,544 71,629 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 (Unaudited) Loan payable -long-term- Related Party On July 5, 2023, the Company and an institutional investor affiliated with one of our directors, Josef Zelinger, entered into a letter agreement, pursuant to which such investor loaned the Company an aggregate of $ 230,000 153,256 3 July 5, 2026 10 250 600 250 141,084 7,140 600 zero 3.00 4.59 268 143,000 Accrued interest from this loan amounted to $ 15,158 46,470 153,256 94,614 58,642 Accrued interest from this loan amounted to $ 22,883 23,686 153,256 70,928 82,328 Loan Payable Crown Bridge Securities Purchase Agreement Effective October 3, 2019, the Company entered into a securities purchase agreement with Crown Bridge Partners, LLC (“Crown Bridge”), pursuant to which Crown Bridge purchased a convertible promissory note from the Company (the “Crown Bridge Note”), which had a remaining principal balance of $ 65,280 15 65,280 43,520 50,477 45,541 Loans Payable - others In June 2024, the Company entered into loan agreements with two investors who loaned the Company an aggregate of $ 120,000 79,811 12 79,811 5,493 665 The aggregate principal outstanding on the above loans was $ 145,091 Loan in default The Crown Bridge Note is currently past due and in default, consisting of $ 65,280 50,477 15

NOTES PAYABLE AND CONVERTIBLE N

NOTES PAYABLE AND CONVERTIBLE NOTES	6 Months Ended
	Dec. 31, 2024
Notes Payable And Convertible Notes
NOTES PAYABLE AND CONVERTIBLE NOTES	NOTE 6 – NOTES PAYABLE AND CONVERTIBLE NOTES Promissory Note On August 15, 2023, the Company issued to an institutional investor (the “August 2023 Lender”) a 10 120,000 132,000 November 15, 2023 10 18 The Company had the right to prepay the principal and accrued but unpaid interest due under the Promissory Note, together with any other amounts that the Company may owe the August 2023 Lender under the terms of the Promissory Note, on or before September 14, 2023 at a 110% premium of the face amount plus accrued and unpaid interest and any other amounts owed to the August 2023 Lender, which increases to (i) 120% if prepaid after such date, but on or before October 14, 2023, and (ii) 130% if prepaid after October 14, 2023 (including on the maturity date), unless the Company and the Lender agree to otherwise effect repayment. 130 18 Accrued interest from this note amounted to $ 24,852 15,536 12,000 132,000 0 132,000 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 (Unaudited) 1800 Diagonal Lending Promissory Notes On May 24, 2024, the Company entered into a 15 49,200 8,200 6,000 35,000 22 28,290 7,072.50 56,580 7,072.50 49,200 5,683 On June 10, 2024, the Company entered into a 15 49,200 8,200 6,000 35,000 22 28,290 7,072.50 56,580 7,072.50 49,200 5,683 The Company had the right to accelerate payments or prepay in full at any time with no prepayment penalty. At any time following an event of default, the noteholder had the right, to convert all or any part of the outstanding and unpaid amount of these notes into shares of common stock. The conversion price of the above notes was equal to 65 35 4.99 150 As of December 31, 2024 and June 30, 2024 the total balance of these 1800 Diagonal Lending promissory notes amounted to $ 0 98,400 0 1,193 Red Road Holdings Promissory Note On December 4, 2024, the Company entered into a 15 49,200 8,200 6,000 35,000 22 28,290 7,072.50 56,580 7,072.50 The Company had the right to accelerate payments or prepay in full at any time with no prepayment penalty. At any time following an event of default, the noteholder has the right, to convert all or any part of the outstanding and unpaid amount of the note into shares of common stock. The conversion price of the note is equal to 65 35 4.99 150 As of December 31, 2024, the total balance of principal and accrued interest of the Red Road Holdings promissory note amounted to $ 49,200 546 The total balance of the above four promissory notes, net of unamortized discount of $ 12,983 168,217 25,706 204,694 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 (Unaudited) Convertible Notes The Company’s convertible notes outstanding at December 31, 2024 and June 30, 2024 were as follows: SCHEDULE OF CONVERTIBLE NOTES December 31, 2024 June 30, 2024 Convertible notes and debenture $ 338,325 $ 313,550 Unamortized discounts (43,819 ) (38,854 ) Premium, net 115,293 124,629 Convertible notes, net $ 409,799 $ 399,325 ONE44 Capital Securities Purchase Agreements August 15, 2022 Securities Purchase Agreement On August 15, 2022, the Company entered into a securities purchase agreement with ONE44, pursuant to which ONE44 purchased a convertible redeemable note (the “August 15, 2022 ONE44 Note”) from the Company in the aggregate principal amount of $ 110,000 10,000 5,500 August 15, 2022 10 February 14, 2023 Securities Purchase Agreement On February 14, 2023, the Company entered into a securities purchase agreement with ONE44, pursuant to which ONE44 purchased a convertible redeemable note (the “February 14, 2023 ONE44 Note”) from the Company in the aggregate principal amount of $ 111,111 11,111 5,500 10 December 8, 2023 Securities Purchase Agreement On December 8, 2023, the Company entered into a securities purchase agreement with ONE44, pursuant to which ONE44 purchased a convertible redeemable note (the “December 8, 2023 ONE44 Note”) from the Company in the aggregate principal amount of $ 150,000 15,000 7,500 10 The following terms shall apply to all of the above ONE44 note: During the first 60 to 180 days following the date of these notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the above notes issued to ONE44, together with any other amounts that the Company may owe ONE44 under the terms of the note, at a premium ranging from 120 135 The conversion price for the above ONE44 notes ranges from 60 65 35 40 4.99 133,305 100,000 The above ONE44 notes contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 24 250 th 500 th 20 The total principal amount outstanding under the above ONE44 financing agreements was $ 119,300 6,726 148,811 9,909 98,311 The total principal amount outstanding under the above ONE44 financing agreements was $ 105,800 12,570 13,500 841 9,000 One ONE44 note with principal amount of $ 105,800 24 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 (Unaudited) GS Capital Partners Securities Purchase Agreements August 23, 2023 Securities Purchase Agreement On August 23, 2023, the Company entered into a securities purchase agreement with GS Capital Partners, LLC, pursuant to which GS Capital purchased a convertible redeemable note from the Company in the aggregate principal amount of $ 77,500 5,000 2,500 The maturity date of the GS Capital Note was February 23, 2024 8 The GS Capital Note was exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note was equal to $2,400 per share, provided that the fixed price will be reduced to $1,200 per share in the event that the market price of the Common Stock trades below $1,800 per share for five consecutive trading days. In the event of a default under the note and unless the fixed price was lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price was subject to re-adjustment every thirty calendar days during the period in which the Company remained in default. The August 23, 2023 GS Capital Note was fully converted in July 2024. October 12, 2023 Securities Purchase Agreement On October 12, 2023, the Company entered into a securities purchase agreement with GS Capital Partners, LLC, pursuant to which GS Capital purchased a convertible redeemable note from the Company in the aggregate principal amount of $ 61,000 3,500 2,500 The maturity date of the GS Capital Note was April 12, 2024 8 The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $900 per share, provided that the fixed price will be reduced to $600 per share in the event that the market price of the Common Stock trades below $450 per share for ten consecutive trading days. In the event of a default under the note and unless the fixed price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default. As of the date of filing this report, such GS Capital Note is past due and currently in default. April 12, 2024 Securities Purchase Agreement On April 12, 2024, the Company entered into a securities purchase agreement with GS Capital Partners, LLC, pursuant to which GS Capital purchased a convertible redeemable note from the Company in the aggregate principal amount of $ 27,500 2,500 The maturity date of the GS Capital Note was October 12, 2024 8 The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $102 per share, provided that the fixed price will be reduced to $60 per share in the event that the market price of the Common Stock trades below $84 per share for five consecutive trading days. In the event of a default under the note and unless the fixed price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default. As of the date of filing this report, such GS Capital Note is past due and currently in default. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 (Unaudited) August 2, 2024 Securities Purchase Agreement On August 2, 2024, the Company entered into a securities purchase agreement with GS Capital Partners, LLC, pursuant to which GS Capital purchased a convertible redeemable note from the Company in the aggregate principal amount of $ 33,000 3,000 The maturity date of the GS Capital Note is February 2, 2025 8 The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $102 per share, provided that the fixed price will be reduced to $60 per share in the event that the market price of the Common Stock trades below $84 per share for five consecutive trading days. In the event of a default under the note and unless the fixed price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default. As of the date of filing this report, such GS Capital Note is past due and currently in default. September 20, 2024 Securities Purchase Agreement On September 20, 2024, the Company entered into a securities purchase agreement with GS Capital Partners, LLC, pursuant to which GS Capital purchased a convertible redeemable note from the Company in the aggregate principal amount of $ 33,000 3,000 The maturity date of the GS Capital Note is March 20, 2025 8 The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $18 per share, provided that the fixed price will be reduced to $6 per share in the event that the market price of the Common Stock trades below $18 per share for five consecutive trading days. In the event of a default under the note and unless the fixed price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default. The following terms shall apply to all of the above GS Capital notes: Pursuant to the above GS Capital notes, in the event that such conversion price is below the par value of the Common Stock, the Company has agreed to take all steps to reduce such par value or conduct a reverse split of its Common Stock, as applicable. Notwithstanding the foregoing, such conversion price and lookback periods are subject to adjustment in favor of the Investor in the event the Company issues securities to another party with more favorable conversion terms, and such conversions are subject to a 4.99 Additionally, the conversion prices of the above GS Capital notes will be adjusted in favor of the note holder if the Company issues securities with more favorable conversion terms. The effective conversion price of the outstanding GS Capital notes are 60 40 The above GS Capital notes were bifurcated from the embedded conversion option which was recorded as derivative liabilities at fair value (see Note 11). During the first 60 to 180 days following the date of the above GS Capital notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the above notes issued to GS Capital, together with any other amounts that the Company may owe GS Capital under the terms of the notes, at a premium ranging from 110 125 Upon the occurrence and during the continuation of certain events of default, interest accrues at a default interest rate of 24 250 th 500 th 20 The total principal outstanding and accrued interest under the above GS Capital notes were $ 110,500 8,364 130,800 8,700 1,254 3,832 110,500 The total principal outstanding and accrued interest under the above GS Capital notes were $ 127,400 11,366 49,100 3,769 66,000 Two GS Capital notes with total principal amounts of $ 61,400 24 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 (Unaudited) 104 LLC Securities Purchase Agreement March 5, 2024 Securities Purchase Agreement Effective March 5, 2024, the Company entered into and closed a securities purchase agreement (the “Purchase Agreement”) with 104 LLC (“104”), pursuant to which 104 agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $ 50,000 46,875 3,125 7,500 March 1, 2025 8 16 June 20, 2024 Securities Purchase Agreement Effective June 20, 2024, Company entered into and closed a securities purchase agreement with 104 LLC, pursuant to which 104 agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $ 33,750 30,375 3,375 5,200 June 20, 2025 8 16 The principal and interest on the notes are convertible into shares of common stock of the Company at the option of 104 at any time following the issuance date of the notes (the “Conversion Shares”) at a price per share equal to 65 35 4.99 45,096 During the first 60 days following the date of the notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the notes, at a one hundred ten percent (110%) premium of the face amount plus accrued and unpaid interest, which increases to (i) one hundred fifteen percent (115%) if prepaid after 60 days, but less than 91 days from the issuance date, (ii) one hundred twenty percent (120%) if prepaid after 90 days, but less than 121 days from the issuance date, (iii) one hundred twenty five percent (125%) if prepaid after 120 days, but less than 181 days from the issuance date. After this initial 180-day period, the Company does not have a right to prepay the notes. The 104 notes contain certain events of default, including failure to pay principal and interest when due, failure to timely issue the conversion shares, failure to maintain the listing of the common stock on at least one of the OTC markets (which specifically includes the quotation platforms maintained by the OTC Markets Group) or an equivalent replacement exchange, failure to comply with its reporting requirements with the U.S. Securities and Exchange Commission, a breach of certain covenants in the purchase agreement, default by the Company under any other note issued to the Investor, as well as certain customary events of default set forth in the notes, including, among others, breach of covenants, representations or warranties, insolvency, bankruptcy, and liquidation. Upon an event of default, the notes will become immediately due and payable by the Company. The total principal amount outstanding under the above 104 financing agreements was $ 83,750 1,429 83,125 1,132 625 4,000 Geebis Consulting Purchase Agreement December 13, 2024 Securities Purchase Agreement On December 13, 2024, the Company entered into a securities purchase agreement with Geebis Consulting, LLC (“Geebis”), pursuant to which Geebis purchased a convertible redeemable note from the Company in the aggregate principal amount of $ 22,000 2,000 The maturity date of the Geebis note is June 15, 2025. The Geebis note shall bear interest at a rate of 8 The Geebis note is exchangeable for an equal aggregate principal amount of note of different authorized denominations, as requested by Geebis surrendering the same. The initial conversion price for the Geebis note is equal to $18 per share, provided that the fixed price will be reduced to $6 per share in the event that the market price of the common stock trades below $18 per share for five consecutive trading days. In the event of default, the conversion price shall be equal to the lowest trading price of the common stock on which the Company’s shares are then traded or any exchange upon which the common stock may be traded in the future. Notwithstanding the foregoing, such conversions are subject to a 4.99% beneficial ownership limitation and adjustments for mergers, consolidations, reorganizations and similar events set forth in the note, other than a transfer or sale of all or substantially all Company assets. Pursuant to the note, the Company is required to maintain an initial reserve of at least 500% of the number of conversion shares, subject to any increase of such reserved amount to reflect the Company’s obligations under the note. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 (Unaudited) Additionally, the conversion price of the Geebis note will be adjusted in favor of the note holder if the Company issues securities with more favorable conversion terms. The effective conversion price of the outstanding Geebis note is 60 40 The above Geebis note was bifurcated from the embedded conversion option which was recorded as derivative liabilities at fair value (see Note 11). During the first 60 to 180 days following the date of the above Geebis note, the Company has the right to prepay the principal and accrued but unpaid interest due under the above notes issued to Geebis, together with any other amounts that the Company may owe Geebis under the terms of the note, at a premium ranging from 110 125 Upon the occurrence and during the continuation of certain events of default, interest accrues at a default interest rate of 24 250 th 500 th 20 The total principal outstanding and accrued interest under the above Geebis note was $ 22,000 87 22,000 Outstanding convertible notes in default Three outstanding convertible notes for total principal amount of $ 167,200 Amortization of debt discounts The Company recorded $ 88,000 186,000 0 234,615 Amortization of all debt discounts for the six months ended December 31, 2024 and 2023 was $ 133,644 164,904 The Company reclassified $ 9,336 87,305

STOCKHOLDERS_ DEFICIT

STOCKHOLDERS’ DEFICIT	6 Months Ended
	Dec. 31, 2024
Equity [Abstract]
STOCKHOLDERS’ DEFICIT	NOTE 7 – STOCKHOLDERS’ DEFICIT Reverse Stock Split On August 7, 2024, the Company received written consent in lieu of a meeting by the holders of a majority of the voting power of the Company’s outstanding capital stock as of August 7, 2024 and the Company’s Board of Directors approving such actions as are necessary for the Company to proceed to, and the Company accordingly intends to, effectuate and execute a reverse stock split of the Company’s issued and outstanding shares of common stock at a ratio of one post-split share per sixty thousand pre-split shares (1:60,000) PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 (Unaudited) Preferred Stock The total number of shares of preferred stock that the Company is authorized to issue is 1,500,005 0.01 Of the total preferred shares authorized, 500,000 On March 15, 2023, the Company filed a certificate with the Secretary of State of Delaware (the “Certificate of Retirement”), effecting the retirement and cancellation of the Series A Preferred Stock to eliminate such Series A Preferred Stock. No no Pursuant to a certificate of designation filed with the Secretary of State of the State of Delaware on June 16, 2015, five shares of preferred stock have been designated as Series B Preferred Stock, par value $ 0.01 One No Common Stock: Shares issued for conversion of convertible debt From July 1, 2024 through September 30, 2024, the Company issued an aggregate of 3,237 12 44,925 7,053 2,548 From October 1, 2024 through December 31, 2024, the Company issued an aggregate of 3,041 6 18,300 1,558 2,034 Included in the above conversion during the six months ended December 31, 2024, were principal aggregate amount of convertible notes of $ 49,100 3,769 2,833 137,454 81,752 51,674 30,078 The Company reclassified $ 9,336 The Company has 124,368 Shares issued for services On August 12, 2024, the Company entered into a consulting agreement with two consultants to provide investor relation services from August 12, 2024 to October 12, 2024 for a total fee of $ 7,500 250 60 15,000 15,000 Restricted Stock Units Pursuant to employment agreements dated in May 2019, the Company granted de minimis restricted stock unit (after the Reverse Stock Split) to the Company’s Chief Executive Officer and Chief Scientific Officer. Such restricted stock units are subject to vesting terms as defined in the employment agreements. Such restricted stock units were valued at the fair value of approximately $ 497,240 248,620 248,620 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 (Unaudited) Stock Warrants: The following table summarizes warrant activity for the six months ended December 31, 2024: SUMMARY OF WARRANT ACTIVITY Weighted Number of Average Shares Price Per Share Outstanding at June 30, 2024 250 $ 74,400 Granted - - Exercised - - Forfeited - - Expired - - Outstanding at December 31, 2024 250 * $ 74,400 Exercisable at December 31, 2024 250 $ 74,400 Outstanding and Exercisable: Weighted average remaining contractual term 1.51 Aggregate intrinsic value $ - * The total warrants of 250 SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE Number of Warrants Exercisable Series A warrants 0.0002 0.0002 Series B warrants 0.0003 0.0003 Series C warrants 0.001 0.0008 Warrants with no class designation 250 250 Total 250 250 Stock Options: During the six months ended December 31, 2024 and 2023, there were no 4.37 On the Effective Date, the Company’s board of directors approved and adopted the Company’s 2019 Equity Incentive Plan (the “2019 Plan”), which reserves a total of 0.004 During the six months ended December 31, 2024 and 2023, the Company recognized stock-based compensation of $ 0 0 No

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 8 – COMMITMENTS AND CONTINGENCIES Legal Matters From time to time, the Company may be subject to litigation and claims arising in the ordinary course of business. The Company is not currently a party to any material legal proceedings and the Company is not aware of any pending or threatened legal proceeding against the Company that we believe could have a material adverse effect on our business, operating results, cash flows or financial condition. IRS Liability As part of its requirement for having a foreign operating subsidiary, the Company is required to file an informational Form 5471 to the Internal Revenue Service (the “IRS”), which is a form that explains the nature of the relationship between the foreign subsidiary and the parent company. From 2012 through the 2014, the Company did not file this form in a timely manner. As a result of the non-timely filings, the Company incurred a penalty from the IRS in the amount of $ 10,000 30,000 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 (Unaudited) Operating Agreements In November 2009, the Company entered into a commercialization agreement with the University of Bath (UK) (the “UK University”), whereby the Company and the UK University co-owned the intellectual property relating to the Company’s pro-enzyme formulations. In June 2012, the Company and the UK University entered into an assignment and amendment whereby the Company assumed full ownership of the intellectual property, while agreeing to pay royalties of 2 5 Collaboration Agreement On September 13, 2018, the Company entered into a two-year collaboration agreement with the University of Jaén (the “University”) to provide certain research On September 13, 2018, the Company entered into a two-year collaboration agreement with the University of Jaén (the “University”) to provide certain research services to the Company. In consideration of such services, the Company agreed to pay the University approximately 52,000 59,508 40,000 45,775 2 On October 1, 2020, the Company entered into another two-year collaboration agreement with the University to provide certain research services to the Company. In consideration of such services, the Company agreed to pay the University approximately 30,000 35,145 5,000 5,000 5,858 10,000 11,715 10,000 11,715 25,837 30,268 2 On July 27, 2022, the Company entered into a two-year research agreement with the University to provide certain research and experiment services to the Company. One of the Company’s Scientific Advisory Board is the lead joint researcher of the University. In exchange for full ownership of the intellectual property, the Company agreed to pay royalties of 1 53,200 53,806 - 18,200 18,407 - 8,000 8,091 - 7,000 7,080 - 10,000 10,114 - 10,000 10,114 The commencement date for the experiments was on September 1, 2022, and the estimated length of time for completion was 24 months. As of December 31, 2024 and June 30, 2024, the Company has $ 48,429 47,531 Consulting Agreement On May 4, 2024, the Company entered into an Engagement Agreement (the “Agreement”) with EF Hutton LLC (the “Consultant”) which will act as an exclusive lead underwriter, financial advisor, placement agent and investment banker of the Company, whereby the Consultant will assist the Company to a public offering and uplisting of the Company’s equity, debt or equity derivative instruments (“Offering”). The engagement period shall end on the earlier of i) 12 months from the date of this agreement or ii) the final closing if any of the Offering. The Consultant will prepare an Underwriting Agreement (the “Underwriting Agreement”) covering the sale of up to $ 15 (a) Financing Fees: (i) For private equity and equity-linked placements, pay the Consultant a cash fee of eight percent ( 8.0 (ii) For debt placements, pay the Consultant a cash fee of six percent ( 6.0 (iii) As additional compensation for EF Hutton’s services, the Company shall issue to the Consultant or its designees at the closing warrants (the “Warrants”) to purchase that number of shares of Common Stock equal to three percent ( 3.0 five years PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 (Unaudited) Additionally, the Consultant shall be entitled to a cash fee equal to eight percent ( 8.0 (b) Merger, acquisition or sale of stock or assets (the “M&A Transaction”) Fees: The M&A Transaction fees shall be payable to the Consultant in cash at the closing or closings of the M&A Transaction to which it relates and shall be equal to five percent ( 5.0 The Company will be responsible for and will pay all expenses relating to the Offering as defined in the Agreement. Additionally, the Company will provide an expense advance (the “Advance”) to the Consultant of $ 50,000 25,000 25,000 25,000 25,000 Operating Leases On May 4, 2022, the Company entered in a three 3,000 2,176 66,201 66,201 8 ROU is summarized below: SCHEDULE OF RIGHT OF USE ASSET December 31, 2024 (Unaudited) June 30, 2024 Office lease $ 66,201 $ 66,201 Less: accumulated amortization (59,624 ) (48,402 ) Right-of-use asset, net $ 6,577 $ 17,799 Operating Lease liabilities are summarized below: SCHEDULE OF OPERATING LEASE LIABILITY December 31, 2024 (Unaudited) June 30, 2024 Office lease $ 66,201 $ 66,201 Reduction of lease liability (58,903 ) (46,839 ) Less: office lease, current portion (7,298 ) (19,362 ) Long term portion of lease liability $ - $ - Remaining future minimum lease payments under non-cancelable operating lease at December 31, 2024 are as follows: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS Fiscal Year 2025 $ 7,420 Imputed interest (122 ) Total operating lease liability $ 7,298 The weighted average remaining lease term for the operating lease is 0.26

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Dec. 31, 2024
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 9 – RELATED PARTY TRANSACTIONS Since its inception, the Company has conducted transactions with its directors and entities related to such directors. These transactions have included the following: As of December 31, 2024 and June 30, 2024, the Company owed its former director a total of $ 27,491 29,759 As of December 31, 2024 and June 30, 2024, the Company owed its former director a total of $ 45,754 49,528 Effective May 5, 2016, the Company entered into an agreement for the lease of its principal executive offices with North Horizon Pty Ltd., a related party, of which Mr. Nathanielsz, our CEO, CFO and a director, and his wife are owners and directors. The lease had a five 39,600 28,325 3,600 2,575 198,000 141,629 3,000 2,176 202,129 124,976 194,129 129,930 13,718 13,006 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 (Unaudited) Loans payable - Related Parties Between November 2023 and May 2024, an institutional investor affiliated with one of our directors, Josef Zelinger, loaned the Company an aggregate of $ 71,629 85,000 57,639 Effective August 1, 2024, the Company entered into and closed a loan agreement (the “Loan”) with an institutional investor affiliated with one of our directors, Josef Zelinger, pursuant to which the investor loaned the Company an aggregate principal amount of $ 150,000 98,060 November 1, 2024 12 18 35 Between November 2024 and December 2024, an institutional investor affiliated with one of our directors, Josef Zelinger, loaned the Company an aggregate of $ 15,000 9,731 Effective December 3, 2024, the Company entered into and closed a loan agreement with an institutional investor affiliated with one of our directors, Josef Zelinger, pursuant to which the investor loaned the Company an aggregate principal amount of $ 175,000 113,485 70,000 105,000 12 18 Loan payable -long-term- Related Party On July 5, 2023, the Company and an institutional investor affiliated with one of our directors, Josef Zelinger, entered into a letter agreement, pursuant to which such investor loaned the Company an aggregate of $ 230,000 153,256 3 July 5, 2026 10 250 600 Employment and Services Agreements with Management The Company and Mr. Nathanielsz entered into an employment agreement as of February 25, 2015 (the “Nathanielsz Employment Agreement”) setting forth the terms and conditions of Mr. Nathanielsz’s employment as the Company’s President and Chief Executive Officer. The Nathanielsz Employment Agreement was scheduled to expire on February 25, 2019 25,000 300,000 205,680 9.5 200 300,000 205,680 400,000 274,240 400,000 309,313 600,000 414,900 Mr. Nathanielsz’s wife, Sylvia Nathanielsz, is and has been a non-executive, part-time employee of the Company since October 2015. Effective February 1, 2018, Mrs. Nathanielsz receives an annual salary of $ 120,000 80,904 Pursuant to a February 25, 2016 board resolution, James Nathanielsz was paid $ 4,481 3,205 17,714 3,344 3,557 2,372 On August 12, 2021, the Board approved a bonus of $ 177,840 221,890 166,418 422,610 316,957 177,840 99 140,000 96,810 73,387 48,905 107,937 71,929 25,000 16,070 150,000 102,195 217,540 145,599 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 (Unaudited) Amended and Restated Employment Agreement On May 14, 2019 (the “Effective Date”), the Company entered into an Amended and Restated Employment Agreement (the “Employment Agreement”) with Mr. Nathanielsz for a term of three years 400,000 309,313 On October 26, 2022, the Company entered into an Amended and Restated Employment Agreement (the “Amended Agreement”) with Mr. Nathanielsz, effective as of July 1, 2022, (the “2022 Effective Date”). The Amended Agreement provides Mr. Nathanielsz with a base salary of $ 600,000 414,900 100 200 Amended and Restated Employment Agreement On May 14, 2019, the Company entered into an Amended and Restated Services Agreement (the “Services Agreement”) with Dr. Kenyon, the Company’s Chief Scientific Officer and a director, for a term of three years 54,000 41,580 As of December 31, 2024 and June 30, 2024, total accrued salaries of $ 175,000 115,395 148,000 97,044 Intercompany Loans All intercompany loans were made by the parent to the Company’s subsidiary, Propanc PTY LTD, none of which has been repaid as of December 31, 2024. Effective fiscal year 2021, the parent company determined that intercompany loans will not be repaid in the foreseeable future and thus, per ASC 830-20-35-3, gains and losses from measuring the intercompany balances are recorded within cumulative translation adjustment on the consolidated balance sheet as accumulated other comprehensive income.

CONCENTRATIONS AND RISKS

CONCENTRATIONS AND RISKS	6 Months Ended
	Dec. 31, 2024
Risks and Uncertainties [Abstract]
CONCENTRATIONS AND RISKS	NOTE 10 – CONCENTRATIONS AND RISKS Concentration of Credit Risk The Company maintains its cash in banks and financial institutions in Australia. Bank deposits in Australian banks are uninsured. The Company has not experienced any losses in such accounts through December 31, 2024. The Company primarily relied on funding from one convertible and two non-convertible debt lenders and received net proceeds after deductions of $ 16,200 60,000 35,000 180,855 98,060 18 10 53 29 The Company primarily relied on funding from five convertible and non-convertible debt lenders and received net proceeds after deductions of $ 73,000 225,000 125,000 127,500 120,000 153,256 30 17 17 16 20 Receivable Concentration As of December 31, 2024 and June 30, 2024, the Company’s receivables were 100 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 (Unaudited) Patent and Patent Concentration The Company has filed multiple patent applications relating to its lead product, PRP. The Company’s lead patent application has been granted and remains in force in the United States, Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Liechtenstein, Turkey, United Kingdom, Australia, China, Japan, Indonesia, Israel, New Zealand, Singapore, Malaysia, South Africa, Republic of Korea, India and Brazil. In Canada and Mexico, the patent applications have been accepted as of fiscal year 2023. In 2016 and early 2017, the Company filed other patent applications. Three applications were filed under the Patent Cooperation Treaty (the “PCT”). The PCT assists applicants in seeking patent protection by filing one international patent application under the PCT, applicants can simultaneously seek protection for an invention in over 150 countries. Once filed, the application is placed under the control of the national or regional patent offices, as applicable, in what is called the national phase. One of the PCT applications filed in November 2016, entered national phase in July 2018 and another PCT application entered national phase in August 2018. A third PCT application entered the national phase in October 2018. In July 2020, a world-first patent was granted in Australia for the cancer treatment method patent family. Presently, there are 84 granted, allowed, or accepted patents and 6 patents filed, or under examination in key global jurisdictions relating to the use of proenzymes against solid tumors, covering the lead product candidate PRP. Further patent applications are expected to be filed to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer. Foreign Operations As of December 31, 2024 and June 30, 2024, the Company’s operations are based in Camberwell, Australia; however, the majority of research and development is being conducted in the European Union. On July 22, 2016, the Company formed a wholly-owned subsidiary, Propanc (UK) Limited under the laws of England and Wales, for the purpose of submitting an orphan drug application with the European Medicines Agency as a small and medium-sized enterprise. As of December 31, 2024 and June 30, 2024, there has been no activity within this entity.

DERIVATIVE FINANCIAL INSTRUMENT

DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	6 Months Ended
	Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	NOTE 11 - DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Derivative Financial Instruments: The Company applies the provisions of ASC 815-40, Contracts in Entity’s Own Equity 149,400 110,500 The Company calculates the estimated fair values of the liabilities for derivative instruments using the Binomial Trees Method. The closing price of the Company’s common stock at December 31, 2024, the last trading day of the period ended December 31, 2024, was $ 10 Convertible Debt SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES Initial Valuations into during the three December 31, 2024 Volatility 295 % 295 % Expected Remaining Term (in years) 0.50 0.01 0.45 Risk Free Interest Rate 4.32 % 4.24 4.40 Expected dividend yield None None PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 (Unaudited) Fair Value Measurements: The Company measures and reports at fair value the liability for derivative instruments. The fair value of liabilities for price adjustable warrants and embedded conversion options have been recorded as determined utilizing the Binomial Trees model. The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2024 and June 30, 2024: SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS Balance at Quoted Prices in Active Markets for Identical Significant Other Observable Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 131,585 $ — $ — $ 131,585 Total $ 131,585 $ — $ — $ 131,585 Balance at Quoted Prices in Active Markets for Identical Significant Other Observable Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 133,886 $ — $ — $ 133,886 Total $ 133,886 $ — $ — $ 133,886 The following is a roll forward for the six months ended December 31, 2024 of the fair value liability of price adjustable derivative instruments: SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE Fair Value of Liability for Derivative Instruments Balance at June 30, 2024 $ 133,886 Initial fair value of embedded conversion option derivative liability recorded as debt discount 80,000 Initial fair value of embedded conversion option derivative liability recorded as derivative expense 35,741 Reduction of derivative liability upon debt conversion (51,674 ) Change in fair value included in statements of operations (66,368 ) Balance at December 31, 2024 $ 131,585

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Dec. 31, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 12 – SUBSEQUENT EVENTS Shares issued for conversion of convertible debt In January 2025, the Company issued an aggregate of 684 6 4,050 403 469

NATURE OF OPERATIONS AND SUMM_2

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES (Policies)	6 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations Propanc Biopharma, Inc. (the “Company,” “we,” “us” or “our”) is based in Camberwell, Victoria Australia. Since its inception, substantially all of the operations of the Company have been focused on the development of new cancer treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to prevent the cancer from returning and spreading. The Company anticipates establishing global markets for its technologies. Our lead product candidate, which we refer to as PRP, is an enhanced pro-enzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. It is currently in the preclinical phase of development. The Company was originally formed in Melbourne, Victoria, Australia on October 15, 2007 as Propanc PTY LTD. On November 23, 2010, Propanc Health Group Corporation was incorporated in the State of Delaware, and in January 2011, to reorganize the Company, all of the outstanding shares of Propanc PTY LTD were acquired on a one-for-one basis by Propanc Health Group Corporation, with Propanc PTY LTD becoming a wholly-owned subsidiary of the Company. On July 22, 2016, the Company formed another wholly-owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose of submitting an orphan drug application to the European Medicines Agency as a small and medium-sized enterprise. As of December 31, 2024, there has been no activity within this entity. Effective April 20, 2017, the Company changed its name to “Propanc Biopharma, Inc.” to reflect the Company’s stage of operations and development better. In July 2020, a world-first patent was granted in Australia for the cancer treatment method patent family. Presently, there are 84 granted, allowed, or accepted patents and 6 patents filed, or under examination in key global jurisdictions relating to the use of proenzymes against solid tumors, covering the lead product candidate PRP. On August 7, 2024, the Company received written consent in lieu of a meeting by the holders of a majority of the voting power of the Company’s outstanding capital stock as of August 7, 2024 and the Company’s Board of Directors approving such actions as are necessary for the Company to proceed to, and the Company accordingly intends to, effectuate and execute a reverse stock split of the Company’s issued and outstanding shares of common stock at a ratio of one post-split share per sixty thousand pre-split shares (1:60,000) The Company hopes to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer by filing additional patent applications as it advances its lead product candidate, PRP, through various stages of development.
Basis of Presentation	Basis of Presentation The Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q (this “Quarterly Report”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly our consolidated results of operations for the six months ended December 31, 2024 and 2023 and cash flows for the six months ended December 31, 2024 and 2023 and our consolidated financial position at December 31, 2024 have been made. The Company’s results of operations for the six months ended December 31, 2024 are not necessarily indicative of the operating results to be expected for the full fiscal year ending June 30, 2025. Certain information and disclosures normally included in the notes to the Company’s annual audited consolidated financial statements have been condensed or omitted from the Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report. Accordingly, these interim unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2024. The June 30, 2024 balance sheet is derived from those statements.
Principles of Consolidation	Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of Propanc Biopharma, Inc., the parent entity, and its wholly-owned subsidiary, Propanc PTY LTD. All inter-company balances and transactions have been eliminated in consolidation. Propanc (UK) Limited was an inactive wholly-owned subsidiary through December 31, 2024 and still remains inactive. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 (Unaudited)
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives of long-lived assets, valuation of the collectability of a refundable advance deposit, present value of the operating lease liability and related right-of-use asset, valuation of derivatives, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates.
Foreign Currency Translation and Other Comprehensive Income (Loss)	Foreign Currency Translation and Other Comprehensive Income (Loss) The Company’s wholly-owned subsidiary’s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into the Company’s reporting currency, which is the United States dollar ($) and/or (USD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “Accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency translations are included in the statements of operations and comprehensive income (loss) as a component of other comprehensive income (loss). There have been no significant fluctuations in the exchange rate for the conversion of Australian dollars to USD after the balance sheet date. Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the consolidated balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency included in the consolidated results of operations as incurred. Effective fiscal year 2021, the parent company determined that the intercompany loans will not be repaid in the foreseeable future and thus, per Accounting Standards Codification (“ASC”) 830-20-35-3, gains and losses from measuring the intercompany balances are recorded within cumulative translation adjustment, a component of accumulated other comprehensive income (loss). As of December 31, 2024 and 2023, the Company recognized a cumulative exchange gain (loss) of approximately ($ 1,573,000 408,000 As of December 31, 2024 and June 30, 2024, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: SCHEDULE OF TRANSACTION EXCHANGE RATES December 31, 2024 June 30, 2024 Exchange rate on balance sheet dates USD : AUD exchange rate 0.6183 0.6693 Average exchange rate for the period USD : AUD exchange rate 0.6594 0.6557 The change in Accumulated Other Comprehensive Income by component during the six months ended December 31, 2024 was as follows: SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME Foreign Balance, June 30, 2024 $ 1,269,581 Unrealized foreign currency translation gain 222,287 Ending balance, December 31, 2024 $ 1,491,868
Fair Value of Financial Instruments and Fair Value Measurements	Fair Value of Financial Instruments and Fair Value Measurements The Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and cash equivalents, receivables, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current interest rates available for debt with similar terms and maturities are substantially the same. The Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Also see Note 11 - Derivative Financial Instruments and Fair Value Measurements. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 (Unaudited)
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the balance sheets. There were no
Refundable Advance Deposit	Refundable Advance Deposit In August 2023, the Company paid a refundable advance deposit of $ 120,958 120,958
Deferred Offering Costs	Deferred Offering Costs The Company complies with the requirements of ASC 340, Other Assets and Deferred Costs, with regards to offering costs. Prior to the completion of an offering, offering costs are capitalized and consist principally of professional, underwriting and other expenses incurred through the balance sheet date that are directly related to the Company’s proposed public offering. The deferred offering costs are charged to additional paid-in capital or as a discount to debt, as applicable, upon the completion of an offering or to expense if the offering is not completed. As of December 31, 2024 and June 30, 2024, the Company had recorded $ 52,117 27,117
Property and Equipment	Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method. The depreciable amount is the cost less its residual value. The estimated useful lives are as follows: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES Machinery and equipment - 5 Furniture - 7
Patents	Patents Patents are stated at cost and amortized on a straight-line basis over the estimated future periods if and once the patent has been granted by a regulatory agency. However, the Company will expense any patent costs as long as we are in the startup stage. Accordingly, as the Company’s products are not currently approved for market, all patent costs incurred from 2013 through December 31, 2024 were expensed immediately. This practice of expensing patent costs immediately ends when a product receives market authorization from a government regulatory agency.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets In accordance with ASC 360-10, “Long-lived assets,” which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable.
Employee Benefit/Liability	Employee Benefit/Liability Liabilities arising in respect of wages and salaries, accumulated annual leave, accumulated long service leave and any other employee benefits expected to be settled within twelve months of the reporting date are measured based on the employee’s remuneration rates applicable at the reporting date. All other employee benefit liabilities are measured at the present value of the estimated future cash outflow to be made in respect of services provided by employees up to the reporting date. All employee liabilities are owed within the next twelve months. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 (Unaudited)
Australian Goods and Services Tax (“GST”)	Australian Goods and Services Tax (“GST”) Revenues, expenses and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office. Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows. As of December 31, 2024 and June 30, 2024, the Company was owed $ 1,973 2,950
Derivative Instruments	Derivative Instruments ASC Topic 815, Derivatives and Hedging
Convertible Notes With Variable Conversion Options	Convertible Notes With Variable Conversion Options The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into shares of the Company’s common stock, par value $ 0.001 Distinguishing Liabilities from Equity
Income Taxes	Income Taxes The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. The Company follows ASC 740 “ Accounting for Income Taxes The Company follows ASC 740, Sections 25 through 60, “ Accounting for Uncertainty in Income Taxes
Research and Development Costs and Tax Credits	Research and Development Costs and Tax Credits In accordance with ASC 730-10, “Research and Development-Overall,” 116,102 130,264 The Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income, then the Company can receive the credit which reduces its income tax liability. If the Company has net losses, then the Company may still receive a cash payment for the credit, however, the Company’s net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as a tax benefit, in operations, upon receipt.
Stock Based Compensation	Stock Based Compensation The Company records stock-based compensation in accordance with ASC 718, “ Stock Compensation The Company adopted ASU 2018-07 and accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period. The Company used the modified prospective method of adoption. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 (Unaudited)
Revenue Recognition	Revenue Recognition The Company applies ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures. Subject to these criteria, the Company intends to recognize revenue relating to royalties on product sales in the period in which the sale occurs and the royalty term has begun.
Legal Expenses	Legal Expenses All legal costs for litigation are charged to expense as incurred.
Leases	Leases The Company follows ASC Topic 842, Leases (Topic 842) and applies the package of practical expedients, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 months or less. Operating lease right of use assets (“ROU”) represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses.
Basic and Diluted Net Loss Per Common Share	Basic and Diluted Net Loss Per Common Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. Each holder of the convertible notes has agreed to a 4.99 SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS December 31, 2024 December 31, 2023 (Unaudited) (Unaudited) Stock Options - - Stock Warrants with no designations 250 250 Series A Warrants as if converted at alternate cashless exercise price 33,173 33,195 Series B Warrants - - Series C Warrants as if converted at alternate cashless exercise price * 152,933 152,933 Unvested restricted stock - - Convertible Debt 44,971 893 Total 231,327 187,271 * Only convertible ratably upon exercise of Series B Warrants
Recent Accounting Pronouncements	Recent Accounting Pronouncements We have reviewed the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. We have carefully considered the new pronouncements that alter previous generally accepted accounting principles and do not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management. In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic 815-40), which eliminates the beneficial conversion and cash conversion accounting models for convertible instruments, amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions, and modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS calculation. The standard is effective for annual periods beginning after December 15, 2023 for smaller reporting companies, and interim periods within those reporting periods. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those reporting periods. The adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements or disclosures.

NATURE OF OPERATIONS AND SUMM_3

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES (Tables)	6 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
SCHEDULE OF TRANSACTION EXCHANGE RATES	As of December 31, 2024 and June 30, 2024, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: SCHEDULE OF TRANSACTION EXCHANGE RATES December 31, 2024 June 30, 2024 Exchange rate on balance sheet dates USD : AUD exchange rate 0.6183 0.6693 Average exchange rate for the period USD : AUD exchange rate 0.6594 0.6557
SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME	The change in Accumulated Other Comprehensive Income by component during the six months ended December 31, 2024 was as follows: SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME Foreign Balance, June 30, 2024 $ 1,269,581 Unrealized foreign currency translation gain 222,287 Ending balance, December 31, 2024 $ 1,491,868
SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES	The estimated useful lives are as follows: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES Machinery and equipment - 5 Furniture - 7
SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS	SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS December 31, 2024 December 31, 2023 (Unaudited) (Unaudited) Stock Options - - Stock Warrants with no designations 250 250 Series A Warrants as if converted at alternate cashless exercise price 33,173 33,195 Series B Warrants - - Series C Warrants as if converted at alternate cashless exercise price * 152,933 152,933 Unvested restricted stock - - Convertible Debt 44,971 893 Total 231,327 187,271 * Only convertible ratably upon exercise of Series B Warrants

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	6 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY PLANT AND EQUIPMENT	Property and equipment consist of the following As of December 31, 2024 and June 30, 2024. SCHEDULE OF PROPERTY PLANT AND EQUIPMENT December 31, 2024 June 30, 2024 (Unaudited) Office equipment at cost $ 23,597 $ 25,543 Less: Accumulated depreciation (23,597 ) (25,543 ) Total property, plant, and equipment $ - $ -

NOTES PAYABLE AND CONVERTIBLE_2

NOTES PAYABLE AND CONVERTIBLE NOTES (Tables)	6 Months Ended
	Dec. 31, 2024
Notes Payable And Convertible Notes
SCHEDULE OF CONVERTIBLE NOTES	The Company’s convertible notes outstanding at December 31, 2024 and June 30, 2024 were as follows: SCHEDULE OF CONVERTIBLE NOTES December 31, 2024 June 30, 2024 Convertible notes and debenture $ 338,325 $ 313,550 Unamortized discounts (43,819 ) (38,854 ) Premium, net 115,293 124,629 Convertible notes, net $ 409,799 $ 399,325

STOCKHOLDERS_ DEFICIT (Tables)

STOCKHOLDERS’ DEFICIT (Tables)	6 Months Ended
	Dec. 31, 2024
Equity [Abstract]
SUMMARY OF WARRANT ACTIVITY	The following table summarizes warrant activity for the six months ended December 31, 2024: SUMMARY OF WARRANT ACTIVITY Weighted Number of Average Shares Price Per Share Outstanding at June 30, 2024 250 $ 74,400 Granted - - Exercised - - Forfeited - - Expired - - Outstanding at December 31, 2024 250 * $ 74,400 Exercisable at December 31, 2024 250 $ 74,400 Outstanding and Exercisable: Weighted average remaining contractual term 1.51 Aggregate intrinsic value $ - * The total warrants of 250
SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE	SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE Number of Warrants Exercisable Series A warrants 0.0002 0.0002 Series B warrants 0.0003 0.0003 Series C warrants 0.001 0.0008 Warrants with no class designation 250 250 Total 250 250

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	6 Months Ended
	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
SCHEDULE OF RIGHT OF USE ASSET	ROU is summarized below: SCHEDULE OF RIGHT OF USE ASSET December 31, 2024 (Unaudited) June 30, 2024 Office lease $ 66,201 $ 66,201 Less: accumulated amortization (59,624 ) (48,402 ) Right-of-use asset, net $ 6,577 $ 17,799
SCHEDULE OF OPERATING LEASE LIABILITY	Operating Lease liabilities are summarized below: SCHEDULE OF OPERATING LEASE LIABILITY December 31, 2024 (Unaudited) June 30, 2024 Office lease $ 66,201 $ 66,201 Reduction of lease liability (58,903 ) (46,839 ) Less: office lease, current portion (7,298 ) (19,362 ) Long term portion of lease liability $ - $ -
SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS	Remaining future minimum lease payments under non-cancelable operating lease at December 31, 2024 are as follows: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS Fiscal Year 2025 $ 7,420 Imputed interest (122 ) Total operating lease liability $ 7,298

DERIVATIVE FINANCIAL INSTRUME_2

DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES	SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES Initial Valuations into during the three December 31, 2024 Volatility 295 % 295 % Expected Remaining Term (in years) 0.50 0.01 0.45 Risk Free Interest Rate 4.32 % 4.24 4.40 Expected dividend yield None None
SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS	SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS Balance at Quoted Prices in Active Markets for Identical Significant Other Observable Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 131,585 $ — $ — $ 131,585 Total $ 131,585 $ — $ — $ 131,585 Balance at Quoted Prices in Active Markets for Identical Significant Other Observable Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 133,886 $ — $ — $ 133,886 Total $ 133,886 $ — $ — $ 133,886
SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE	The following is a roll forward for the six months ended December 31, 2024 of the fair value liability of price adjustable derivative instruments: SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE Fair Value of Liability for Derivative Instruments Balance at June 30, 2024 $ 133,886 Initial fair value of embedded conversion option derivative liability recorded as debt discount 80,000 Initial fair value of embedded conversion option derivative liability recorded as derivative expense 35,741 Reduction of derivative liability upon debt conversion (51,674 ) Change in fair value included in statements of operations (66,368 ) Balance at December 31, 2024 $ 131,585

SCHEDULE OF TRANSACTION EXCHANG

SCHEDULE OF TRANSACTION EXCHANGE RATES (Details)	Dec. 31, 2024	Jun. 30, 2024
Property, Plant and Equipment [Line Items]
Foreign currency exchange rate, translation	0.6183	0.6693
Weighted Average [Member]
Property, Plant and Equipment [Line Items]
Foreign currency exchange rate, translation	0.6594	0.6557

SCHEDULE OF ACCUMULATED OTHER C

SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME (Details)	6 Months Ended
	Dec. 31, 2024 USD ($)
Accounting Policies [Abstract]
Beginning balance	$ 1,269,581
Unrealized foreign currency translation loss	222,287
Ending balance	$ 1,491,868

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES (Details)	Dec. 31, 2024
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	7 years

SCHEDULE OF ANTI-DILUTIVE SECUR

SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS (Details) - shares		6 Months Ended
		Dec. 31, 2024	Dec. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		231,327	187,271
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		250	250
Series A Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		33,173	33,195
Series B Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities
Series C Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	[1]	152,933	152,933
Unvested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		44,971	893
[1]Only convertible ratably upon exercise of Series B Warrants

NATURE OF OPERATIONS AND SUMM_4

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES (Details Narrative) - USD ($)		3 Months Ended		6 Months Ended
	Aug. 07, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Jun. 30, 2024	Aug. 31, 2023
Accounting Policies [Abstract]
Reverse stock split	one post-split share per sixty thousand pre-split shares (1:60,000)
Foreign currency transaction, gain (loss)				$ 1,573,000	$ 408,000
Cash and cash equivalents		$ 0		0		$ 0
Refundable advance deposit							$ 120,958
Allowance for recoverability of refundable advance deposit				120,958
Deferred offering cost		52,117		52,117		27,117
GST tax receivable		$ 1,973		$ 1,973		$ 2,950
Common stock, par value		$ 0.001		$ 0.001		$ 0.001
Research and development costs		$ 54,388	$ 114,022	$ 116,102	$ 130,264
Beneficial ownership conversion description				Each holder of the convertible notes has agreed to a 4.99% beneficial ownership conversion limitation (subject to certain noteholders’ ability to increase such limitation to 9.99% upon 60 days’ notice to the Company), and each note may not be converted during the first six-month period from the date of issuance
Beneficial ownership percentage				4.99%

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended
	Dec. 31, 2024	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2024	Dec. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 430,183	$ 354,310	$ 584,384	$ 350,866	$ 784,493	$ 935,250
Net cash used in operations					241,786	572,342
Working capital deficit	4,136,980				4,136,980
Stockholders' deficit	4,158,759	$ 4,108,085	$ 3,563,599	$ 2,989,259	4,158,759	$ 3,563,599	$ 3,779,059	$ 3,117,179
Accumulated deficit	$ 67,482,713				$ 67,482,713		$ 66,698,220

SCHEDULE OF PROPERTY PLANT AND

SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details) - USD ($)	Dec. 31, 2024	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
Office equipment at cost	$ 23,597	$ 25,543
Less: Accumulated depreciation	(23,597)	(25,543)
Total property, plant, and equipment

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Depreciation expense		$ 248

DUE TO FORMER DIRECTOR - RELA_2

DUE TO FORMER DIRECTOR - RELATED PARTY (Details Narrative) - USD ($)	Dec. 31, 2024	Jun. 30, 2024
Former Director [Member]
Defined Benefit Plan Disclosure [Line Items]
Due to related parties current	$ 27,491	$ 29,759

LOANS (Details Narrative)

LOANS (Details Narrative)				2 Months Ended		3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 03, 2024 USD ($)	Aug. 01, 2024 USD ($)	Jul. 05, 2023 USD ($) $ / shares shares	Dec. 31, 2024 USD ($)	Dec. 31, 2024 AUD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Jun. 30, 2024 USD ($)	Dec. 31, 2024 AUD ($)	Dec. 03, 2024 AUD ($)	Aug. 31, 2024 USD ($)	Aug. 31, 2024 AUD ($)	Aug. 01, 2024 AUD ($)	Jun. 30, 2024 AUD ($)	May 31, 2024 USD ($)	Apr. 02, 2024 AUD ($)	Feb. 28, 2024 AUD ($)	Nov. 30, 2023 USD ($)	Jul. 05, 2023 AUD ($) shares	Oct. 03, 2019
Debt instrument face amount				$ 49,100		$ 49,100		$ 49,100					$ 57,639	$ 85,000			$ 71,629			$ 71,629
Debt instrument strike price								4.99%
Settlement of convertible debt									$ 142,909
Interest payable current and non current				3,769		3,769		3,769
Amortization of debt discounts								133,644	164,904
Debt remaining				338,325		338,325		338,325		$ 313,550
Remaining debt discount				43,819		43,819		43,819		38,854
Gain on extinguishment of debt						(18,759)	$ (211)	(30,078)	34,099
Crown Bridge Partners, LLC [Member]
Debt instrument face amount				$ 65,280		$ 65,280		$ 65,280
Debt instrument interest rate stated percentage				15%		15%		15%			15%
Interest payable current and non current				$ 50,477		$ 50,477		$ 50,477
Loan Agreement [Member]
Loans payable				145,091		145,091		145,091		145,091								$ 105,000	$ 70,000
Debt instrument face amount	$ 113,485	$ 98,060		9,731		9,731		9,731		$ 79,811	$ 15,000	$ 175,000			$ 150,000	$ 120,000
Debt instrument maturity date		Nov. 01, 2024
Debt instrument loan bears interest rate	12%	12%
Debt instrument interest rate stated percentage	18%	18%								12%		18%			18%	12%
Debt instrument strike price		35%
Interest payable current and non current				5,493		5,493		5,493		$ 665
Debt remaining				79,811		79,811		79,811		79,811
Letter Agreement [Member]
Debt instrument face amount			$ 153,256																		$ 230,000
Debt instrument maturity date			Jul. 05, 2026
Debt instrument interest rate stated percentage			10%																		10%
Maturity term			3 years
Warrants to purchase shares | shares			250																		250
Share price | $ / shares			$ 600
Issue of warrants | shares			250
Fair value adjustment of warrants			$ 141,084
Letter Agreement [Member] | Coventry Enterprises LLC Securities Purchase Agreement [Member]
Settlement of convertible debt								143,000
Letter Agreement [Member] | Warrant [Member]
Stock valuation price per share | $ / shares			$ 7,140
Warrant exercise price | $ / shares			$ 600
Letter Agreement [Member] | Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement input			0																		0
Letter Agreement [Member] | Warrant [Member] | Measurement Input, Expected Term [Member]
Maturity term			3 years
Letter Agreement [Member] | Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement input			4.59																		4.59
Letter Agreement [Member] | Warrant [Member] | Measurement Input, Price Volatility [Member]
Measurement input			268																		268
Securities Purchase Agreement [Member]
Amortization of debt discounts								88,000	$ 186,000
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member]
Debt instrument face amount				65,280		65,280		65,280		65,280
Debt instrument interest rate stated percentage																						15%
Interest payable current and non current				50,477		50,477		50,477		45,541
Convertible debt										65,280
Gain on extinguishment of debt								43,520
Related Party [Member]
Loans payable				45,754		45,754		45,754		49,528
Loan payable				350,544		350,544		350,544		71,629			$ 57,639	$ 85,000			$ 71,629			$ 71,629
Loan payable				9,731	$ 15,000
Interest payable current and non current				22,883		22,883		22,883		15,158
Amortization of debt discounts								23,686		46,470
Debt remaining				153,256		153,256		153,256		153,256
Remaining debt discount				70,928		70,928		70,928		94,614
Loan payable - long-term - related party, net of discount				$ 82,328		$ 82,328		$ 82,328		$ 58,642

SCHEDULE OF CONVERTIBLE NOTES (

SCHEDULE OF CONVERTIBLE NOTES (Details) - USD ($)	Dec. 31, 2024	Jun. 30, 2024
Notes Payable And Convertible Notes
Convertible notes and debenture	$ 338,325	$ 313,550
Unamortized discounts	(43,819)	(38,854)
Premium, net	115,293	124,629
Convertible notes, net	$ 409,799	$ 399,325

NOTES PAYABLE AND CONVERTIBLE_3

NOTES PAYABLE AND CONVERTIBLE NOTES (Details Narrative)																							6 Months Ended		12 Months Ended
	Jul. 15, 2025 USD ($)	Jun. 15, 2025 USD ($)	Jan. 15, 2025 USD ($)	Dec. 30, 2024 USD ($)	Dec. 15, 2024 USD ($)	Dec. 13, 2024 USD ($)	Dec. 04, 2024 USD ($)	Nov. 30, 2024 USD ($)	Sep. 20, 2024 USD ($)	Aug. 02, 2024 USD ($)	Jun. 20, 2024 USD ($)	Jun. 10, 2024 USD ($)	May 24, 2024 USD ($)	May 07, 2024	Apr. 12, 2024 USD ($)	Mar. 05, 2024 USD ($)	Dec. 08, 2023 USD ($)	Oct. 12, 2023 USD ($)	Aug. 23, 2023 USD ($)	Aug. 15, 2023 USD ($)	Feb. 14, 2023 USD ($)	Aug. 15, 2022 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jan. 31, 2025 USD ($)	Aug. 31, 2024 USD ($)	Aug. 31, 2024 AUD ($)	May 31, 2024 USD ($)	May 04, 2024	Nov. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)
Principal amount																							$ 49,100				$ 57,639	$ 85,000	$ 71,629		$ 71,629
Accrued interest																							3,769
Amortization of debt discount																							133,644	$ 164,904
Debt remaining																							338,325		$ 313,550
Debt instrument unamortized discount																							43,819		38,854
Note payable, net of discount																							168,217		204,694
Debt premium																							115,293		124,629
Penalty amount																							30,000
Fee amount																							2,833
Derivative liabilities																							131,585		133,886
Conversion of stock amount converted																							9,336	87,305
Maximum [Member]
Debt instrument interest rate percentage																														8%
Securities Purchase Agreement [Member]
Amortization of debt discount																							88,000	186,000
Debt premium																							0	234,615
Convertible Notes One [Member]
Amortization of debt discount																							$ 133,644	$ 164,904
Subsequent Event [Member]
Principal amount																										$ 4,050
Accrued interest																										403
Fee amount																										$ 469
1800 Diagonal Lending LLC [Member]
Debt instrument original issue discount rate												15%	15%										150%
Original issue discounts amount												$ 8,200	$ 8,200
Principal amount								$ 49,200				$ 49,200	$ 49,200
Debt instrument interest rate percentage												22%	22%
Accrued interest								5,683															$ 0		1,193
Debt remaining																							$ 0		98,400
Legal and financing costs												$ 6,000	$ 6,000
Net proceeds												$ 35,000	$ 35,000
Debt periodic payment								28,290
Principal amount				$ 7,072.50				7,072.50
Payment of debt								56,580
Debt instrument conversion rate																							65%
Debt instrument discount rate																							35%
Ownership limitations																							4.99%
1800 Diagonal Lending LLC [Member] | Subsequent Event [Member]
Principal amount			$ 7,072.50
ONE44 Capital LLC [Member]
Accrued interest																							$ 841		9,909
Debt premium																									100,000							$ 133,305
ONE44 Capital LLC [Member] | Securities Purchase Agreement [Member]
Principal amount																	$ 150,000				$ 111,111	$ 110,000	$ 105,800		119,300
Debt instrument maturity date																						Aug. 15, 2022
Debt instrument interest rate percentage																	10%				10%	10%	24%
Accrued interest																							$ 12,570		6,726
Debt instrument unamortized discount																	$ 15,000				$ 11,111	$ 10,000
Ownership limitations																	4.99%
Legal fees																	$ 7,500				$ 5,500	$ 5,500
Debt premium																							9,000		98,311
Default interest rate																	24%
Debt instrument increase principal percentage																	20%
Debt conversion converted instrument																							13,500		148,811
ONE44 Capital LLC [Member] | Securities Purchase Agreement [Member] | Minimum [Member]
Penalty amount																	120%
Debt instrument conversion rate																	60%
Debt instrument discount rate																	35%
Penalty amount																	$ 250
ONE44 Capital LLC [Member] | Securities Purchase Agreement [Member] | Maximum [Member]
Penalty amount																	135%
Debt instrument conversion rate																	65%
Debt instrument discount rate																	40%
Penalty amount																	$ 500
GS Capital Partners, LLC [Member]
Penalty amount									24%
Accrued interest																							3,769		8,700
Derivative fixed interest rate																									1,254
GS Capital Partners, LLC [Member] | Securities Purchase Agreement [Member]
Principal amount									$ 33,000	$ 33,000					$ 27,500			$ 61,000	$ 77,500
Debt instrument maturity date									Mar. 20, 2025	Feb. 02, 2025					Oct. 12, 2024			Apr. 12, 2024	Feb. 23, 2024
Debt instrument interest rate percentage									8%	8%					8%			8%	8%
Accrued interest																							11,366		8,364
Debt remaining																							$ 127,400		110,500
Debt instrument unamortized discount									$ 3,000	$ 3,000					$ 2,500			$ 3,500	$ 5,000
Debt instrument conversion rate									60%
Debt instrument discount rate									40%
Ownership limitations																							4.99%
Legal fees																		$ 2,500	$ 2,500
Debt instrument increase principal percentage									20%
Conversion price, description									The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $18 per share, provided that the fixed price will be reduced to $6 per share in the event that the market price of the Common Stock trades below $18 per share for five consecutive trading days. In the event of a default under the note and unless the fixed price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default.	The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $102 per share, provided that the fixed price will be reduced to $60 per share in the event that the market price of the Common Stock trades below $84 per share for five consecutive trading days. In the event of a default under the note and unless the fixed price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default. As of the date of filing this report, such GS Capital Note is past due and currently in default.					The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $102 per share, provided that the fixed price will be reduced to $60 per share in the event that the market price of the Common Stock trades below $84 per share for five consecutive trading days. In the event of a default under the note and unless the fixed price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default. As of the date of filing this report, such GS Capital Note is past due and currently in default.			The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $900 per share, provided that the fixed price will be reduced to $600 per share in the event that the market price of the Common Stock trades below $450 per share for ten consecutive trading days. In the event of a default under the note and unless the fixed price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default. As of the date of filing this report, such GS Capital Note is past due and currently in default.	The GS Capital Note was exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note was equal to $2,400 per share, provided that the fixed price will be reduced to $1,200 per share in the event that the market price of the Common Stock trades below $1,800 per share for five consecutive trading days. In the event of a default under the note and unless the fixed price was lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price was subject to re-adjustment every thirty calendar days during the period in which the Company remained in default. The August 23, 2023 GS Capital Note was fully converted in July 2024.
Fee amount																									3,832
Derivative liabilities																							$ 66,000		110,500
GS Capital Partners, LLC [Member] | Securities Purchase Agreement [Member] | Minimum [Member]
Penalty amount									110%
Penalty amount									$ 250
GS Capital Partners, LLC [Member] | Securities Purchase Agreement [Member] | Maximum [Member]
Penalty amount									125%
Penalty amount									$ 500
GS Capital Partners, LLC [Member] | August 10, 2017 Consulting Agreement [Member]
Debt conversion converted instrument																							$ 49,100		130,800
Coventry Enterprises LLC Securities Purchase Agreement [Member] | Securities Purchase Agreement [Member]
Penalty amount																							24%
Amount repaid for covertible debt																							$ 61,400
104 LLC [Member] | Securities Purchase Agreement [Member]
Principal amount											$ 33,750					$ 50,000
Debt instrument maturity date											Jun. 20, 2025					Mar. 01, 2025
Debt Instrument description											the notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the notes, at a one hundred ten percent (110%) premium of the face amount plus accrued and unpaid interest, which increases to (i) one hundred fifteen percent (115%) if prepaid after 60 days, but less than 91 days from the issuance date, (ii) one hundred twenty percent (120%) if prepaid after 90 days, but less than 121 days from the issuance date, (iii) one hundred twenty five percent (125%) if prepaid after 120 days, but less than 181 days from the issuance date. After this initial 180-day period, the Company does not have a right to prepay the notes.
Accrued interest																							1,132		1,429
Debt remaining																							83,125		83,750
Debt instrument unamortized discount											$ 3,375					$ 3,125
Legal and financing costs											$ 5,200					7,500
Principal amount																							4,000
Debt instrument conversion rate											65%
Debt instrument discount rate											35%
Ownership limitations											4.99%
Debt premium																									45,096
Purchase amount											$ 30,375					$ 46,875
Principal amount																							625
104 LLC [Member] | Securities Purchase Agreement [Member] | Minimum [Member]
Debt instrument interest rate percentage											8%					8%
104 LLC [Member] | Securities Purchase Agreement [Member] | Maximum [Member]
Debt instrument interest rate percentage											16%					16%
Geebis Consulting LLC [Member] | Securities Purchase Agreement [Member]
Penalty amount						24%
Accrued interest																							87
Debt remaining																							22,000
Debt instrument unamortized discount						$ 2,000
Debt instrument conversion rate						60%
Debt instrument discount rate						40%
Debt instrument increase principal percentage						20%
Debt conversion converted instrument						$ 22,000																	22,000
Geebis Consulting LLC [Member] | Securities Purchase Agreement [Member] | Minimum [Member]
Penalty amount						110%
Penalty amount						$ 250
Geebis Consulting LLC [Member] | Securities Purchase Agreement [Member] | Maximum [Member]
Penalty amount						125%
Penalty amount						$ 500
Geebis Consulting LLC [Member] | Forecast [Member] | Securities Purchase Agreement [Member]
Debt instrument interest rate percentage		8%
Conversion price, description		The Geebis note is exchangeable for an equal aggregate principal amount of note of different authorized denominations, as requested by Geebis surrendering the same. The initial conversion price for the Geebis note is equal to $18 per share, provided that the fixed price will be reduced to $6 per share in the event that the market price of the common stock trades below $18 per share for five consecutive trading days. In the event of default, the conversion price shall be equal to the lowest trading price of the common stock on which the Company’s shares are then traded or any exchange upon which the common stock may be traded in the future. Notwithstanding the foregoing, such conversions are subject to a 4.99% beneficial ownership limitation and adjustments for mergers, consolidations, reorganizations and similar events set forth in the note, other than a transfer or sale of all or substantially all Company assets. Pursuant to the note, the Company is required to maintain an initial reserve of at least 500% of the number of conversion shares, subject to any increase of such reserved amount to reflect the Company’s obligations under the note.
Loans Payable [Member]
Debt instrument original issue discount rate																				10%
Original issue discounts amount																				$ 120,000
Principal amount																				$ 132,000
Debt instrument maturity date																				Nov. 15, 2023
Debt instrument interest rate percentage																				10%
Interest rate increase decrease																				18%
Debt Instrument description																				The Company had the right to prepay the principal and accrued but unpaid interest due under the Promissory Note, together with any other amounts that the Company may owe the August 2023 Lender under the terms of the Promissory Note, on or before September 14, 2023 at a 110% premium of the face amount plus accrued and unpaid interest and any other amounts owed to the August 2023 Lender, which increases to (i) 120% if prepaid after such date, but on or before October 14, 2023, and (ii) 130% if prepaid after October 14, 2023 (including on the maturity date), unless the Company and the Lender agree to otherwise effect repayment.
Debt Instrument, Interest Rate During Period														130%
Penalty amount																				18%
Accrued interest																							24,852		15,536
Amortization of debt discount																									12,000
Debt remaining																							132,000		132,000
Debt instrument unamortized discount																							0		0
Note payable, net of discount																							132,000
Loans Payable [Member] | Promissory Note [Member]
Debt remaining																							168,217		204,694
Debt instrument unamortized discount																							$ 12,983		$ 25,706
Loans Payable [Member] | 1800 Diagonal Lending LLC [Member]
Principal amount								49,200
Accrued interest								$ 5,683
Debt periodic payment					$ 28,290
Principal amount					7,072.50
Payment of debt					$ 56,580
Red Road Holdings Promissory Note [Member]
Debt instrument original issue discount rate							15%																150%
Original issue discounts amount							$ 8,200
Principal amount							$ 49,200
Debt instrument interest rate percentage							22%
Accrued interest																							$ 546
Debt remaining																							49,200
Legal and financing costs							$ 6,000
Net proceeds							35,000
Debt periodic payment							28,290
Principal amount							$ 7,072.50
Debt instrument conversion rate							65%
Debt instrument discount rate							35%
Ownership limitations							4.99%
Red Road Holdings Promissory Note [Member] | Forecast [Member]
Principal amount	$ 7,072.50
Red Road Holdings Promissory Note [Member] | Subsequent Event [Member]
Payment of debt		$ 56,580
Convertible Notes Payable [Member]
Convertible note																							$ 167,200

SUMMARY OF WARRANT ACTIVITY (De

SUMMARY OF WARRANT ACTIVITY (Details)	6 Months Ended
	Dec. 31, 2024 USD ($) $ / shares shares
Equity [Abstract]
Number of Shares, Outstanding, Balance | shares	250
Weighted Average Price Per Share, Outstanding, Balance | $ / shares	$ 74,400
Number of Shares, Granted | shares
Weighted Average Price Per Share, Granted | $ / shares
Number of Shares, Exercised | shares
Weighted Average Price Per Share, Exercised | $ / shares
Number of Shares, Forfeited | shares
Weighted Average Price Per Share, Forfeited | $ / shares
Number of Shares, Expired | shares
Weighted Average Price Per Share, Expired | $ / shares
Number of Shares, Outstanding, Balance | shares	250	[1]
Weighted Average Price Per Share, Outstanding, Ending balance | $ / shares	$ 74,400
Number of Shares, Exercisable, Balance | shares	250
Weighted Average Price Per Share, Exercisable, Balance | $ / shares	$ 74,400
Weighted average remaining contractual term	1 year 6 months 3 days
Aggregate intrinsic value | $
[1]The total warrants of 250

SCHEDULE OF WARRANT ACTIVITY (D

SCHEDULE OF WARRANT ACTIVITY (Details) (Parenthetical) - shares	Dec. 31, 2024		Jun. 30, 2024
Equity [Abstract]
Number of Shares, Outstanding, Balance	250	[1]	250
[1]The total warrants of 250

SCHEDULE OF WARRANT OUTSTANDING

SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE (Details) - shares	Dec. 31, 2024		Jun. 30, 2024
Class of Stock [Line Items]
Number of Warrants, Total	250	[1]	250
Exercisable, Total	250
Series A Warrants [Member]
Class of Stock [Line Items]
Number of Warrants, Total	0.0002
Exercisable, Total	0.0002
Series B Warrants [Member]
Class of Stock [Line Items]
Number of Warrants, Total	0.0003
Exercisable, Total	0.0003
Series C Warrants [Member]
Class of Stock [Line Items]
Number of Warrants, Total	0.001
Exercisable, Total	0.0008
Common Stock Warrants With No Class Designation [Member]
Class of Stock [Line Items]
Number of Warrants, Total	250
Exercisable, Total	250
[1]The total warrants of 250

STOCKHOLDERS_ DEFICIT (Details

STOCKHOLDERS’ DEFICIT (Details Narrative)		1 Months Ended	2 Months Ended	3 Months Ended			6 Months Ended		12 Months Ended
	Aug. 07, 2024	May 31, 2019 $ / shares	Oct. 12, 2024 USD ($) $ / shares shares	Dec. 31, 2024 USD ($) $ / shares shares	Sep. 30, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($)	Dec. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) shares	Jun. 30, 2024 USD ($) $ / shares shares	Aug. 31, 2024 USD ($)	Aug. 31, 2024 AUD ($)	May 31, 2024 USD ($)	Nov. 30, 2023 USD ($)	Mar. 31, 2023 shares
Class of Stock [Line Items]
Stockholders equity reverse stock split	sixty thousand pre-split shares (1:60,000)
Preferred stock, shares authorized | shares				1,500,005			1,500,005		1,500,005
Preferred stock, par value | $ / shares				$ 0.01			$ 0.01		$ 0.01
Principal amount				$ 49,100			$ 49,100			$ 57,639	$ 85,000	$ 71,629	$ 71,629
Accrued interest				3,769			3,769
Conversion fees				2,833			2,833
Loss on extinguishment debt conversion				81,752			81,752
Debt conversion fair value				51,674			51,674
Gain (loss) on extinguishment of debt				$ 18,759		$ 211	30,078	$ (34,099)
Reclassified from premium liabilities to additional paid in capital							$ 9,336
Common stock, par value | $ / shares				$ 0.001			$ 0.001		$ 0.001
Number of shares issued, value
Number of Shares | shares							0	0
Weighted average remaining contractual term							4 years 4 months 13 days
Company recognized stock-based compensation				$ 0		0	$ 0	$ 0
Unvested stock option expense				$ 0		$ 0	$ 0	$ 0
Stock options granted | shares							0
2019 Equity Incentive Plan [Member]
Class of Stock [Line Items]
Number of common shares reserved for future issuance | shares				0.004			0.004
Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Restricted stock units, value | $ / shares		$ 497,240
Unrecognized restricted stock units expense							$ 248,620		$ 248,620
Restricted stock units not yet vested, shares				$ 248,620			$ 248,620
Underlying Financing Agreements [Member]
Class of Stock [Line Items]
Number of common shares reserved for future issuance | shares				124,368			124,368
Consulting Agreement [Member]
Class of Stock [Line Items]
Number of shares issued | shares			250
Monthly Fee			$ 7,500
Common stock, par value | $ / shares			$ 60
Number of shares issued, value			$ 15,000
Prepaid stock-based compensation							$ 15,000
Convertible Debt [Member]
Class of Stock [Line Items]
Number of shares issued | shares				3,041	3,237
Average contractual conversion prices | $ / shares				$ 6	$ 12		$ 6
Principal amount				$ 18,300	$ 44,925		$ 18,300
Accrued interest				1,558	7,053		1,558
Conversion fees				2,034	$ 2,548		2,034
Debt instrument fair value				$ 137,454			$ 137,454
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized | shares				500,000			500,000
Preferred stock shares outstanding | shares				0			0		0					0
Preferred stock shares issued | shares				0			0		0
Shares issued | shares				0			0		0
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized | shares				5			5		5
Preferred stock, par value | $ / shares				$ 0.01			$ 0.01		$ 0.01
Preferred stock shares outstanding | shares				1			1		1
Preferred stock shares issued | shares				1			1		1
Shares issued | shares				0			0		0

SCHEDULE OF RIGHT OF USE ASSET

SCHEDULE OF RIGHT OF USE ASSET (Details) - Related Party [Member] - USD ($)	Dec. 31, 2024	Jun. 30, 2024
Defined Benefit Plan Disclosure [Line Items]
Office lease	$ 66,201	$ 66,201
Less: accumulated amortization	(59,624)	(48,402)
Right-of-use asset, net	$ 6,577	$ 17,799

SCHEDULE OF OPERATING LEASE LIA

SCHEDULE OF OPERATING LEASE LIABILITY (Details) - Related Party [Member] - USD ($)	Dec. 31, 2024	Jun. 30, 2024
Defined Benefit Plan Disclosure [Line Items]
Office lease	$ 66,201	$ 66,201
Reduction of lease liability	(58,903)	(46,839)
Less: office lease, current portion	(7,298)	(19,362)
Long term portion of lease liability

SCHEDULE OF FUTURE MINIMUM LEAS

SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details)	Dec. 31, 2024 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Fiscal Year 2025	$ 7,420
Imputed interest	(122)
Total operating lease liability	$ 7,298

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Narrative)

1 Months Ended

6 Months Ended

May 04, 2024 USD ($)

Jul. 27, 2022 USD ($)

Jul. 27, 2022 EUR (€)

May 04, 2022 USD ($)

May 04, 2022 AUD ($)

Oct. 01, 2020 USD ($)

Oct. 01, 2020 EUR (€)

Sep. 13, 2018 USD ($)

Sep. 13, 2018 EUR (€)

Jul. 31, 2023 USD ($)

Jul. 31, 2023 EUR (€)

Mar. 31, 2023 USD ($)

Mar. 31, 2023 EUR (€)

Dec. 31, 2022 USD ($)

Dec. 31, 2022 EUR (€)

Sep. 30, 2022 USD ($)

Sep. 30, 2022 EUR (€)

Aug. 31, 2022 USD ($)

Aug. 31, 2022 EUR (€)

Dec. 31, 2021 USD ($)

Dec. 31, 2021 EUR (€)

Mar. 31, 2021 USD ($)

Mar. 31, 2021 EUR (€)

Nov. 30, 2020 EUR (€)

Jun. 30, 2012

Dec. 31, 2024 USD ($)

Dec. 31, 2023 USD ($)

Jun. 30, 2024 USD ($)

Total litigation penalty amount

$ 30,000

Royalties percentage

2%

2%

Unreimbursed lab fees

48,429

$ 47,531

Warrants term

5 years

Deferred offering cost

52,117

$ 27,117

Payments for rent

$ 13,718

$ 13,006

Incremental borrowing rate

8%

8%

Weighted average remaining lease term

3 months 3 days

Accounting Standards Update 2016-02 [Member]

Operating lease right of use asset

$ 66,201

Operating lease liabilities

$ 66,201

Consultant [Member]

Sale of stock percent

5%

Expenses advance

$ 50,000

Deferred offering cost

$ 25,000

$ 25,000

Maximum [Member]

Cash fee percentage

8%

Common Stock [Member]

Sale of stock percent

3%

Equity and Equity Linked Placements [Member]

Cash fee percentage

8%

Debt Placements [Member]

Cash fee percentage

6%

University of Jaen [Member]

Payment for services

$ 30,268

€ 25,837

Royalty Agreement Terms [Member]

Operating leases income statement revenue percentage

2%

License Agreement Terms [Member]

Operating leases income statement revenue percentage

5%

1-Year Collaboration Agreement [Member]

Payment for services

$ 59,508

€ 52,000

2-Year Collaboration Agreement [Member]

Payment for services

$ 35,145

€ 30,000

$ 45,775

€ 40,000

Royalty percentage

2%

2%

Research Agreement [Member] | University of Jaen [Member]

Payment for services

$ 53,806

€ 53,200

Royalty percentage

1%

1%

Underwriting Agreement [Member] | EF Hutton LLC [Member]

Sale of underwriting agreements

$ 15,000,000

Merger Acquisition Agreement [Member] | Consultant [Member]

Expenses advance

25,000

Initial Payable [Member] | Consultant [Member]

Expenses advance

$ 25,000

New Three-Year Operating Lease Agreement [Member]

Lessee operating lease term

3 years

Payments for rent

$ 2,176

$ 3,000

From 2012 through the 2014 [Member]

Total litigation penalty amount

$ 10,000

Installment 1 [Member] | 2-Year Collaboration Agreement [Member]

Payment for services | €

€ 5,000

Installment 1 [Member] | Research Agreement [Member]

Payment for services

$ 18,407

€ 18,200

Installment 2 [Member] | 2-Year Collaboration Agreement [Member]

Payment for services

$ 5,858

€ 5,000

Installment 2 [Member] | Research Agreement [Member]

Payment for services

$ 8,091

€ 8,000

Installment 3 [Member] | 2-Year Collaboration Agreement [Member]

Payment for services

$ 11,715

€ 10,000

Installment 3 [Member] | Research Agreement [Member]

Payment for services

$ 7,080

€ 7,000

Installment 4 [Member] | 2-Year Collaboration Agreement [Member]

Payment for services

$ 11,715

€ 10,000

Installment 4 [Member] | Research Agreement [Member]

Payment for services

$ 10,114

€ 10,000

Installment 5 [Member] | Research Agreement [Member]

Payment for services

$ 10,114

€ 10,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative)																							1 Months Ended		6 Months Ended			12 Months Ended
	Dec. 03, 2024 USD ($)	Aug. 01, 2024 USD ($)	Jul. 05, 2023 USD ($) $ / shares shares	Oct. 26, 2022 USD ($)	Oct. 26, 2022 AUD ($)	Aug. 01, 2022 USD ($)	Aug. 01, 2022 AUD ($)	May 04, 2022 USD ($)	May 04, 2022 AUD ($)	Aug. 12, 2021 USD ($) shares	May 14, 2019 USD ($)	May 14, 2019 AUD ($)	Mar. 16, 2018 USD ($)	Mar. 16, 2018 AUD ($)	Feb. 01, 2018 USD ($)	Feb. 01, 2018 AUD ($)	May 05, 2016 USD ($)	May 05, 2016 AUD ($)	Feb. 25, 2016 USD ($)	Feb. 25, 2016 AUD ($)	Feb. 25, 2015 USD ($)	Feb. 25, 2015 AUD ($)	Jan. 31, 2024 USD ($)	Jan. 31, 2024 AUD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2024 AUD ($)	Dec. 31, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2024 AUD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2023 AUD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2021 AUD ($)	Dec. 31, 2024 AUD ($)	Dec. 03, 2024 AUD ($)	Aug. 31, 2024 USD ($)	Aug. 31, 2024 AUD ($)	Aug. 01, 2024 AUD ($)	Jun. 30, 2024 AUD ($)	May 31, 2024 USD ($)	May 04, 2024	Apr. 02, 2024 AUD ($)	Feb. 28, 2024 AUD ($)	Nov. 30, 2023 USD ($)	Jul. 05, 2023 AUD ($)	May 05, 2016 AUD ($)
Related Party Transaction [Line Items]
Payments for rent																									$ 13,718		$ 13,006
Investor loan, value																									$ 49,100											$ 57,639	$ 85,000			$ 71,629				$ 71,629
Debt instrument strike price																									4.99%	4.99%
Bonus payable																							$ 102,195	$ 150,000				$ 16,070	$ 25,000	$ 48,905	$ 73,387
Accrued salaries																									$ 115,395			97,044						$ 175,000					$ 148,000
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Bonus payable																																$ 166,418	$ 221,890
Remaining bonus amount																									145,599	$ 217,540		145,599	217,540	$ 71,929	$ 107,937
Maximum [Member]
Related Party Transaction [Line Items]
Debt instrument interest rate stated percentage																																									8%
Loan Agreement [Member]
Related Party Transaction [Line Items]
Investor loan, value	$ 113,485	$ 98,060																							9,731			$ 79,811						$ 15,000	$ 175,000			$ 150,000	$ 120,000
Debt instrument maturity date		Nov. 01, 2024
Debt instrument loan bears interest rate	12%	12%
Debt instrument interest rate stated percentage	18%	18%																										12%							18%			18%	12%
Debt instrument strike price		35%
Loans payable																									$ 145,091			$ 145,091														$ 105,000	$ 70,000
Letter Agreement [Member]
Related Party Transaction [Line Items]
Investor loan, value			$ 153,256																																										$ 230,000
Debt instrument maturity date			Jul. 05, 2026
Debt instrument interest rate stated percentage			10%																																										10%
Term of agreement			3 years
Issue of warrants | shares			250
Share price | $ / shares			$ 600
Nathanielsz Employment Agreement [Member]
Related Party Transaction [Line Items]
Expired date																					Feb. 25, 2019	Feb. 25, 2019
Base salary per month																						$ 25,000
Annual salary				$ 414,900	$ 600,000																$ 205,680	$ 300,000
Percentage of pension of monthly salary																														9.50%	9.50%
Percentage of bonus of annual base salary																									200%	200%
Nathanielsz Employment Agreement [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Annual salary						$ 414,900	$ 600,000						$ 274,240	$ 400,000
Percentage of bonus of annual base salary																					200%	200%			100%	100%
Nathanielsz Employment Agreement [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Annual salary						309,313	400,000						$ 205,680	$ 300,000
Mrs. Nathanielsz [Member] | Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Bonus payable																																$ 316,957	$ 422,610
North Horizon Pty Ltd [Member]
Related Party Transaction [Line Items]
Lessee, operating lease, term of contract																	5 years																													5 years
Operating leases rent expense, minimum rentals																	$ 28,325	$ 39,600
Goods and service tax																	2,575	$ 3,600
Payments for rent																									$ 124,976	$ 202,129		129,930	$ 194,129
North Horizon Pty Ltd [Member] | Three Year Operating Lease Agreement [Member]
Related Party Transaction [Line Items]
Payments for rent								$ 2,176	$ 3,000
Former Director [Member]
Related Party Transaction [Line Items]
Loans from related party																									27,491			29,759
Due to related parties																									45,754			49,528
Nathanielsz [Member] | North Horizon Pty Ltd [Member]
Related Party Transaction [Line Items]
Operating leases, future minimum payments due																	$ 141,629																													$ 198,000
Mrs. Nathanielsz [Member]
Related Party Transaction [Line Items]
Annual salary															$ 80,904	$ 120,000
Payments form related party																									$ 2,372	$ 3,557		$ 17,714		$ 3,344
James Nathanielsz [Member]
Related Party Transaction [Line Items]
Payments form related party																			$ 3,205	$ 4,481
Mr. Nathanielsz [Member] | Board of Directors [Member]
Related Party Transaction [Line Items]
Officers compensation						$ 96,810	$ 140,000			$ 177,840
Debt conversion, converted instrument, shares issued | shares										99
Mr. Nathanielsz [Member] | Employment Agreement [Member]
Related Party Transaction [Line Items]
Annual salary											$ 309,313	$ 400,000
Dr. Kenyon [Member] | Services Agreement [Member]
Related Party Transaction [Line Items]
Annual salary											$ 41,580	$ 54,000
Agreement term											3 years	3 years

CONCENTRATIONS AND RISKS (Detai

CONCENTRATIONS AND RISKS (Details Narrative) - USD ($)	6 Months Ended		12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Jun. 30, 2024
Concentration Risk [Line Items]
Discounts and debt issuance cost	$ 16,200	$ 73,000
Proceeds from convertible promissory notes	$ 80,000	$ 477,500
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender One [Member]
Concentration Risk [Line Items]
Concentration risk percentage	18%	30%
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender Two [Member]
Concentration Risk [Line Items]
Concentration risk percentage	10%	17%
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender Three [Member]
Concentration Risk [Line Items]
Concentration risk percentage	53%	17%
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender Four [Member]
Concentration Risk [Line Items]
Concentration risk percentage	29%	16%
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender Five [Member]
Concentration Risk [Line Items]
Concentration risk percentage		20%
Accounts Receivable [Member] | Credit Concentration Risk [Member] | Receivable [Member]
Concentration Risk [Line Items]
Concentration risk percentage	100%		100%
Lender One [Member]
Concentration Risk [Line Items]
Proceeds from convertible promissory notes	$ 60,000	$ 225,000
Lender Two [Member]
Concentration Risk [Line Items]
Proceeds from convertible promissory notes	35,000	125,000
Lender Three [Member]
Concentration Risk [Line Items]
Proceeds from convertible promissory notes	180,855	127,500
Lender Four [Member]
Concentration Risk [Line Items]
Proceeds from convertible promissory notes	$ 98,060	120,000
Lender Five [Member]
Concentration Risk [Line Items]
Proceeds from convertible promissory notes		$ 153,256

SCHEDULE OF FAIR VALUE MEASUREM

SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES (Details) - Convertible Debt [Member]	6 Months Ended
	Dec. 31, 2024
Measurement Input, Price Volatility [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, percentages	295
Measurement Input, Price Volatility [Member] | New Derivative Instruments [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, percentages	295
Measurement Input, Expected Term [Member] | Minimum [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, term	3 days
Measurement Input, Expected Term [Member] | Maximum [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, term	5 months 12 days
Measurement Input, Expected Term [Member] | New Derivative Instruments [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, term	6 months
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, percentages	4.24
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, percentages	4.40
Measurement Input, Risk Free Interest Rate [Member] | New Derivative Instruments [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, percentages	4.32

SCHEDULE OF FAIR VALUE, ASSETS

SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) - USD ($)	Dec. 31, 2024	Jun. 30, 2024
Platform Operator, Crypto Asset [Line Items]
Embedded conversion option liabilities	$ 131,585	$ 133,886
Total	131,585	133,886
Fair Value, Inputs, Level 1 [Member]
Platform Operator, Crypto Asset [Line Items]
Embedded conversion option liabilities
Total
Fair Value, Inputs, Level 2 [Member]
Platform Operator, Crypto Asset [Line Items]
Embedded conversion option liabilities
Total
Fair Value, Inputs, Level 3 [Member]
Platform Operator, Crypto Asset [Line Items]
Embedded conversion option liabilities	131,585	133,886
Total	$ 131,585	$ 133,886

SCHEDULE OF DERIVATIVE LIABILIT

SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Beginning balance			$ 133,886
Change in fair value included in statements of operations	$ (13,581)	$ 1,771	(66,368)	$ (302,158)
Ending balance	131,585		131,585
Derivative [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Beginning balance			133,886
Initial fair value of embedded conversion option derivative liability recorded as debt discount			80,000
Initial fair value of embedded conversion option derivative liability recorded as derivative expense			35,741
Reduction of derivative liability upon debt conversion			(51,674)
Change in fair value included in statements of operations			(66,368)
Ending balance	$ 131,585		$ 131,585

DERIVATIVE FINANCIAL INSTRUME_3

DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Details Narrative) - USD ($)	Dec. 31, 2024	Jun. 30, 2024
Derivative Instruments, Gain (Loss) [Line Items]
Share price	$ 10
Convertible Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Convertible debt	$ 149,400	$ 110,500

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative)	Jan. 31, 2025 USD ($) $ / shares shares	Dec. 31, 2024 USD ($)	Aug. 31, 2024 USD ($)	Aug. 31, 2024 AUD ($)	May 31, 2024 USD ($)	Nov. 30, 2023 USD ($)
Subsequent Event [Line Items]
Principal amount		$ 49,100	$ 57,639	$ 85,000	$ 71,629	$ 71,629
Accrued interest		3,769
Conversion fees		$ 2,833
Subsequent Event [Member]
Subsequent Event [Line Items]
New issuance, shares | shares	684
Debt instrument contractual conversion price | $ / shares	$ 6
Principal amount	$ 4,050
Accrued interest	403
Conversion fees	$ 469